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adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor 
activity against soft-tissue sarcoma. International Journal of Cancer. 2015, 
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II  SIURALA M, Vähä-Koskela M, Havunen R, Tähtinen S, Bramante S, Parviainen 
S, Mathis JM, Kanerva A, Hemminki A. Syngeneic Syrian hamster tumors feature 
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18;5(5). 
III  SIURALA M, Havunen R, Saha D, Lumen D, Airaksinen AJ, Tähtinen S, Cervera-
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A. Adenoviral delivery of tumor necrosis factor alpha and interleukin-2 enables 
successful adoptive cell therapy of immunosuppressive melanoma. Molecular 
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IV  Havunen R, SIURALA M, Parviainen S, Grönberg-Vähä-Koskela S, Behr M, 
Tähtinen S, Santos J, Rusanen J, Nettelbeck D, Ehrhardt A, Kanerva A, Hemminki 
A. Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-
2 enable successful adoptive cell therapy with tumor-infiltrating lymphocytes. 
Molecular Therapy – Oncolytics. Accepted for publication.  
 
 
Publication I was included in the thesis of Simona Bramante (Oncolytic Adenovirus Coding for 
GM-CSF in Treatment of Cancer, University of Helsinki, 2015). 
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ABSTRACT 
 
New treatment modalities are needed for patients with advanced cancer, who have undergone 
several unsuccessful pretreatments. Cancer immunotherapy has emerged as a promising field of 
medicine with the potential to induce durable responses in these patients. Within the 
immunotherapy field, a diverse set of approaches have been employed, all of which aim at 
combating tumors with the cells of the immune system. Oncolytic immunotherapy encompasses 
the use of genetically engineered viruses to specifically kill (lyse) tumor cells and, importantly, to 
induce an antitumor immune response in the process. Oncolytic adenoviruses in particular possess 
an excellent safety profile and can be armed with immunostimulatory transgenes for the 
enhancement of antitumor immunity.  
In the first part of the thesis, oncolytic adenovirus armed with granulocyte-macrophage colony-
stimulating factor (GMCSF) was used together with the chemotherapeutic agents doxorubicin and 
ifosfamide to treat soft-tissue sarcoma (STS) in an adenovirus-permissive Syrian hamster model. 
The combination treatment was highly effective against syngeneic hamster leiomyosarcoma 
tumors in vivo, with indications that adenovirus replication was improved in the presence of 
doxorubicin and that oncolytic adenovirus/chemotherapy combination induced immunogenic cell 
death (ICD) of tumor cells.  
Tumor-infiltrating lymphocytes (TIL) from syngeneic Syrian hamster tumors were cultured, 
characterized and used therapeutically with oncolytic adenovirus in the second part of the thesis. 
Co-treatment of pancreatic cancer tumors with adoptive transfer of pancreatic cancer –derived 
TIL and oncolytic adenovirus resulted in improved antitumor efficacy when compared with either 
monotherapy. 
In the third part, non-replicating adenovirus vectors coding for the murine cytokines tumor 
necrosis factor alpha (TNFa) and interleukin 2 (IL-2) were constructed and used in combination 
with adoptive transfer of tumor-specific T-cell receptor –engineered (TCR) T-cells for the 
treatment of immunosuppressive melanoma. This combination showed significant antitumor 
efficacy over single agent treatments. Mechanistic studies revealed that intratumoral virus 
injections induce trafficking of adoptively transferred T-cells to tumors. Furthermore, the 
cytokine-coding adenoviruses caused favorable alterations in the tumor microenvironment.  
In the final part of the thesis, oncolytic adenoviruses coding for human versions of TNFa and IL-
2 were used with hamster TIL to successfully treat pancreatic cancer tumors. In fact, virus 
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injections were capable of eliminating most tumors when combined TIL transfer, and protected 
cured hamsters from tumor rechallenge. From a safety perspective it is noteworthy that virus-
mediated cytokine production was restricted to tumors, as negligible levels of cytokines were 
observed in the sera of intratumorally injected animals.   
In conclusion, the combinatorial approach studied in the preclinical setting here represents a 
rational and effective solution for the treatment of advanced solid tumors, warranting the clinical 
translation of adenovirus-based immunotherapy combined with other immunotherapies.  
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PART B 
1. REVIEW OF THE LITERATURE 
 
1.1. Introduction 
Cancer is set to become the major cause of mortality in every region of the world, as new cases 
are projected to increase dramatically by the year 2030 (Vineis & Wild 2014). Even though cure 
rates have improved significantly during the 20th century with the advent of chemotherapy and 
radiotherapy, many cancers survive the first, second, third and even fourth-line standard 
treatments to eventually become death-causing diseases. Thus, new treatment options are sorely 
needed for these patients whose disease has metastasized to multiple sites and are not within reach 
of current therapies. 
Development of genetic engineering methods has revolutionized the way new targets for cancer 
therapy are being discovered (Helmy et al. 2013). Among emerging treatment modalities, cancer 
immunotherapy aims to enable the immune system to effectively recognize and attack cancerous 
cells (Farkona et al. 2016). Immunotherapy has developed rapidly into a promising field of 
medicine. Although considered a relatively new field, its origins could be dated back to Edward 
Jenner´s smallpox vaccine in the 1700s (Riedel 2005), and perhaps more appropriately to William 
B. Coley´s mixed bacterial vaccine, or “Coley´s toxin”, in the late 1800s (Wiemann & Starnes 
1994). Multiple approaches have been taken to empower the immune system to fight cancer; from 
immunostimulatory cytokines to adoptive T-cell transfer, and more recently, oncolytic viruses.  
Although many of these modalities have shown promising signs of efficacy, further work is 
needed to find combinations of immunotherapies that complement each other for optimal 
treatment outcome. 
 
1.2 Chemotherapy 
The term “chemotherapy” was first coined in the early 1900s by German chemist Paul Ehrlich, 
who was developing drugs for infectious diseases (DeVita & Chu 2008). He was also interested 
in cancer therapy with primitive alkylating agents. It was not until World War II that the field 
started to truly develop. Soldiers accidentally exposed to sulfur mustards were markedly depleted 
of bone marrow and lymph nodes, which eventually led to development of oral derivatives of 
nitrogen mustard for lymphoma treatment. Further discoveries in the field led eventually to the 
use of combinations of chemotherapeutics for solid tumors as well, e.g. advanced breast cancer 
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and testicular cancer, with encouraging results. Since the early years, combinatorial use has 
matured significantly and is now used in several indications as standard treatment. However, 
toxicities related to chemotherapeutics have limited their use from the beginning, and another 
drawback of chemotherapy is the establishment of resistance, which can lead to tumor progression 
and eventually death. Drug resistance is associated with overexpression of P-glycoprotein, a 
transmembrane drug efflux pump (Malhotra & Perry 2003). Nevertheless, chemotherapeutic 
regimens remain a valuable tool for oncologists alongside other conventional treatment 
modalities. 
 
1.2.1 Doxorubicin and ifosfamide 
The combination of doxorubicin and ifosfamide has been the standard first-line chemotherapy 
regimen for STS since the late 1970s (Ratan & Patel 2016). Doxorubicin, an anthracycline 
antibiotic, acts by intercalating the base pairs of DNA´s double helix, resulting in ceased DNA 
replication and RNA transcription, and subsequent cell death (Tacar et al. 2013). Cardiotoxicity 
is the main toxic effect induced by doxorubicin due to enlargening of cardiomyocytes. Other 
common side effects associated with doxorubicin administration include vomiting, nausea, 
gastrointestinal problems and neurological disturbances. Ifosfamide, like its cousin 
cyclophosphamide, works by alkylating (adding of alkyl group) DNA bases thus impairing DNA 
replication and/or transcription (Puyo et al. 2014). Ifosfamide and cyclophospamide belong to 
oxazaphorines which are derivatives of nitrogen mustards, but enhanced for stability and safety 
(Giraud et al. 2010). They are prodrugs, meaning that they require activation in the liver by 
cytochrome P450 enzymes to yield active metabolites (Preissner et al. 2015). The main serious 
adverse effects of ifosfamide are nephrotoxicity and bladder toxicity (Korkmaz et al. 2007), which 
necessitates the simultaneous use of Mesna (2-mercaptoethane sulfonate) to counter toxicities 
(Salman et al. 2016). 
As mentioned above, doxorubicin and ifosfamide in combination are used in the treatment of soft-
tissue sarcomas. These malignancies are rare and heterogeneous, as they can arise from several 
soft tissue types (Quesada & Amato 2012). Surgery and radiotherapy can be effective for local 
resected disease, but for metastatic disease the aforementioned chemotherapy combination is most 
widely used, although temozolomide and gemcitabine are also used (Awada et al. 2004, Reed & 
Altiok 2011). The well-established doxorubicin plus ifosfamide standard therapy was recently 
challenged, however, as the single largest Phase III clinical trial performed in STS (EORTC 
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62012) indicated that single agent doxorubicin was in fact as effective as doxorubicin combined 
with ifosfamide (Judson et al. 2014). 
 
1.2.2 Immunogenic cell death 
Some chemotherapeutics possess features beyond direct cytotoxicity, for which they were 
originally developed. The cancer cell death modality they trigger is called immunogenic cell death 
(ICD), a variant of apoptosis, which is sensed by the innate immune system and contributes to the 
overall antitumor activity of chemotherapy (Galluzzi et al. 2012). ICD is characterized by three 
major cellular events: 1) cell-surface exposure of calreticulin, 2) extracellular HMGB1 (high 
mobility group box 1 protein) release, and 3) extracellular ATP (adenosine triphosphate) release 
(Kepp et al. 2014) (Figure 1). These damage-associated molecular patterns (DAMPs) bind to 
pattern recognition receptors (PRRs) on immune cells to exert immunostimulatory effects 
(Zitvogel et al. 2010). 
The earliest event in ICD is the translocation of calreticulin, one of the most abundant proteins in 
the endoplasmic reticulum (ER), to the surface of the dying cell (Obeid et al. 2007). Membrane-
exposed calreticulin delivers a phagocytic “eat-me” signal to antigen-presenting cells (APC) 
improving their capability to take up dead tumor cells. Extracellular ATP in turn acts as a 
chemoattractant to immune cells per se, but also activates the NLR family pyrin domain 
containing 3 (NLRP3) inflammasome in APCs leading to release of IL-1b and IL-18 (Ghiringhelli 
et al. 2009). Released HMGB1 binds to Toll-like receptors (TLR) on APCs thus stimulating the 
production of proinflammatory cytokines (Andersson et al. 2000, Tesniere et al. 2008). 
Interestingly, the redox status of HMGB1 seems to determine its immunomodulatory role 
(Venereau et al. 2012). Reduced HMGB1 triggers immunogenic DCs, but oxidized HMGB1 fails 
to do so. Since the tumor microenvironment features an unstable redox milieu, conflicting reports 
on the effect of HMGB1 for antitumor immunity could be explained by these fluctuations (Inoue 
& Tani 2013). The clinically approved chemotherapeutic drugs that have been confirmed to 
induce immunogenic cancer cell death are bleomycin, bortezomib, cyclophosphamide, 
doxorubicin, epirubicin, idarubicin, mitoxantrone and oxaliplatin (Pol et al. 2015b). It is 
noteworthy that doxorubicin was in fact the “prototype” drug when chemotherapy-induced ICD 
was first discovered (Casares et al. 2005). 
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Figure 1. Immunogenic cell death. A cancer cell exposed to chemotherapeutic agents (and/or 
oncolytic adenovirus) translocates calreticulin (CRT) to the cell surface and secretes ATP and 
HMGB1. These signals activate dendritic cells to take up tumor-associated antigens (TAAs) 
released from the dying cell, ultimately leading to T-cell activation. 
 
1.3 Oncolytic viruses 
Oncolytic viruses are viruses that are capable of specifically infecting and lysing tumor cells 
(Breitbach et al. 2016). To date, a plethora of viruses from various genera have been utilized as 
oncolytics, either as genetically modified agents (e.g. vaccinia virus, adenovirus) or wild-type 
viruses possessing natural tropism for cancer cells (e.g. reovirus) (Zamarin & Pesonen 2015). In 
addition to their direct lytic properties, they have emerged as potent activators of antitumor 
immune responses that are important for optimal efficacy. Over 20 years of development in the 
field recently led to the first Food and Drug Administration (FDA) and European Medicines 
Agency (EMEA) approved GMCSF-expressing oncolytic herpes virus therapeutic, Imlygic® 
(talimogene laherparepvec), for advanced melanoma (Breitbach et al. 2016). Many others are 
currently in randomized clinical trials, including Pexa-vec (poxvirus) and Reolysin® (reovirus) 
(Pol et al. 2015a). The focus of this thesis was on adenovirus, which will therefore be discussed 
in detail hereafter. 
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1.3.1 Adenovirus biology 
Adenovirus particles were first isolated in the 1950s from adenoid tissue (Rowe et al. 1953). It is 
a common virus that causes upper respiratory tract infections, pneumonia, bronchitis and 
conjuctivitis (Kunz & Ottolini 2010). The over 50 identified serotypes (belonging to six groups 
named from A to F) are each associated with different clinical manifestations. Also, the 
seroprevalence in the adult population varies significantly (Schmitz et al. 1983). Serotype 5 
adenovirus (member of group C) is the most frequently used vector in gene therapy studies, due 
to its well-known functions and structure (Appaiahgari & Vrati 2015). By comparison, serotype 
3 has utility in cancer gene therapy applications owing to its lower seroprevalence and the high 
expression of serotype 3 receptors on cancer cells (Hemminki et al. 2011). Lower seroprevalence 
is desirable, since pre-existing neutralizing antibodies limit the efficacy of systemic adenovirus 
gene therapy (Uusi-Kerttula et al. 2015). 
Structurally, adenovirus is a non-enveloped double-stranded DNA virus with an icosahedral 
protein capsid (Nemerow et al. 2009) (Figure 2). Out of the 40 different proteins that the 36 kb 
genome encodes, only 12 are involved with virus particle construction (Lehmberg et al. 1999). 
The outer part of the virus is formed by 240 trimers of hexon, the major capsid protein. The two 
other major capsid proteins are penton base and fiber. Penton base is a pentameric molecule that 
associates with the fiber protein, which in turn is formed of shaft and knob parts that are 
responsible for host cell attachment (Law & Davidson 2005). Minor capsid proteins pIX, pIIIa, 
pVI and pVIII have been proposed to help stabilize the virus capsid (Saban et al. 2006). Inside the 
virion, core proteins pV, pVII, pX (or μ) and terminal protein (TP) are associated with the DNA 
genome. 
Adenovirus life cycle can be considered to start from binding to host cell. This process involves 
the knob proteins on the virus and the coxsackie-adenovirus receptors (CAR) (for serotype 5) or 
desmoglein 2 (DSG-2) (for serotype 3) on the host cell surface (Bergelson et al. 1997, Wang et 
al. 2011). After binding to high-affinity receptors, the virus enters the cell via clathrin-mediated 
endocytosis (Smith et al. 2010). Once internalized, the virus particles inside endosomes are 
stripped of capsid proteins due to the acidic environment. The resulting partially uncoated virus 
particle is transported to the nucleus along microtubules. Finally, the viral genome is released into 
the nucleus. Here, the expression of viral genes begins and new virions are generated. 
Adenovirus transcription is a two-phase event, consisting of early and late phases (Russell 2000). 
E1 (early) genes E1A and E1B are first expressed and these proteins interfere with cell division 
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processes to favor virus replication. E2 gene products provide the machinery for viral DNA 
replication (Hay et al. 1995). The E3-derived proteins subvert host defence mechanisms and are 
thus dispensable in in vitro situations (Russell 2000). E4 gene products shut off host protein 
synthesis, promote virus DNA replication and facilitate virus mRNA metabolism (Halbert et al. 
1985). Finally, the late genes L1-L5, encoding structural proteins needed for virion assembly, are 
transcribed (Russell 2000). As the last step in the life cycle of adenovirus, the host cell is lysed 
and new virions are released. 
 
 
Figure 2. Structure of adenovirus. 
 
1.3.2 Oncolytic adenoviruses 
As adenoviruses have no natural tropism for tumor cells, genetic engineering techniques are 
needed to modify them for this purpose. Two approaches are employed to produce viruses with 
specificity to tumor cells: transcriptional and transductional targeting (Alemany 2009). In 
transcriptional targeting, viral gene expression is controlled with tumor-specific promoters, 
whereas in transductional targeting the virus capsid is modified for increased affinity for tumor 
cells. Preclinical and clinical use of oncolytic adenovirus has demonstrated the safety and efficacy 
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of this form of cancer therapy, with indications that arming the viruses with immunostimulatory 
molecules induces beneficial changes in the tumor microenvironment (Cerullo et al. 2010a, Ranki 
et al. 2014, Vassilev et al. 2015, Ranki et al. 2016). 
 
1.3.2.1 Transcriptional and transductional targeting 
In transcriptional targeting, small deletions made to the adenovirus E1A gene render the virus 
specific to cancer cells with regard to replication (Pesonen et al. 2011). The ONYX-015 virus, 
with deletions in the E1B-55k gene, was one of the first of its kind and exhibited cell killing 
specific to p53-mutated cells (Bischoff et al. 1996). Another E1A-deleted virus, Delta24, featured 
a 24-base pair deletion in the retinoblastoma (Rb) binding region of E1A (Fueyo et al. 2000). This 
renders the virus incapable of replicating in normal cells with intact Rb/p16 pathway which by 
contrast is defective in cancer cells (Sherr & McCormick 2002). In normal cells the deleted E1A 
is unable to bind Rb and to release the transcription factor E2F, which is required for replication 
to start. However, in cancer cells the abundantly available E2F transcomplements the mutated 
E1A thus enabling virus replication to proceed. 
In addition to E1A deletions, tumor-specific promoters can be incorporated into adenovirus 
genomes to restrict virus replication to tumors. For example, prostate tumors expressing prostate-
specific antigen (PSA) have been targeted successfully in this way (Rodriguez et al. 1997). 
Melanoma has been targeted by controlled E1A expression by the tyrosinase promoter (Nettelbeck 
et al. 2002). Alpha-fetoprotein (AFP) –producing hepatocellular carcinoma has been used as target 
for tumor-specific viruses (Li et al. 2001, Kim et al. 2002, Kwon et al. 2010), and colorectal cancer 
has been targeted by a carcinoembryonic antigen (CEA) –specific promoter (Li et al. 2003). A set 
of more broadly usable promoters have also been studied including E2F (Hemminki et al. 2015, 
Yan et al. 2015), vascular endothelial growth factor (VEGF) (Rein et al. 2004, Kanerva et al. 
2008), human telomerase reverse transcriptase (hTERT) (Diaconu et al. 2012, Hemminki et al. 
2012) and cyclooxygenase (Cox-2) (Pesonen et al. 2010). 
As described earlier, transductional targeting aims to modify the adenovirus capsid proteins to 
improve binding and entry to tumor cells. Several modification strategies have been studied; some 
addressing the problem of low CAR expression (the primary Ad5 receptor) on tumor cells that 
inhibits effective entry (Hemminki et al. 2003), and some de-targeting the liver where hepatic 
macrophages (Kupffer cells) take up and neutralize adenovirus particles (Tao et al. 2001). 
Insertion of an RGD-motif in the HI loop of the fiber knob enables virus entry through integrins 
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that are abundantly expressed on many cancer cells (Kangasniemi et al. 2006). Heparan sulfate 
proteoglycans present in many tumors have been targeted with adenoviruses containing a COOH-
terminal polylysine tail (Kleeff et al. 1998, Ranki et al. 2007). In adapter-based targeting, a 
“molecular bridge” is generated between the cell surface receptor and the adenovirus particle 
(Glasgow et al. 2006). Examples of this approach include an adenovirus construct that targeted 
malignant cells expressing folate receptors (Douglas et al. 1996), and bispecific antibodies that 
bridged pulmonary endothelial cells to adenovirus vectors (Reynolds et al. 2000). 
An effective approach to improve cancer cell transduction is the modification of the fiber knob to 
feature components of different serotypes, also called fiber knob chimerism or serotype fiber 
switching (Everts & Curiel 2004). In the 5/3 chimeric capsid construct the shaft part is derived 
from serotype 5 and the knob from serotype 3, which has been shown to transduce cancer cells 
efficiently (Krasnykh et al. 1996, Kanerva et al. 2002). The 5/3 chimeric virus has been studied 
extensively in preclinical and clinical settings with promising results in various indications (Guse 
et al. 2007, Bramante et al. 2014, Bramante et al. 2015). In another approach, Ad5/35 chimeric 
adenovirus that targets the CD46 receptor instead of CAR showed effective tumor transduction 
(Liu et al. 2009). More recently, an Ad5/11 virus carrying the interleukin-24 (IL-24) transgene 
exhibited potent antitumor efficacy against acute myeloid leukemia (AML) (Wei et al. 2015). 
Liver sequestration of adenovirus has been shown to depend on the fiber protein (Nicklin et al. 
2005). For this reason, serotype 5 –based viruses with a shorter fiber shaft from serotype 3 were 
constructed and demonstrated attenuated liver uptake after intravenous administration 
(Breidenbach et al. 2004). Similarly, when the native fiber shaft of Ad5 was genetically shortened, 
significantly lower liver uptake was observed in vivo (Vigne et al. 2003). 
 
1.3.2.2 Immunological aspects 
Adenovirus particles (like any virus particles) are sensed as “non-self” when an infection occurs, 
which leads to an immediate innate immune response against the virus followed by an adaptive 
immune response (Fausther-Bovendo & Kobinger 2014). Adenovirus is considered one of the 
most immunogenic of viruses, inducing robust adaptive immune responses (Afkhami et al. 2016). 
Various PRRs, including TLR 4 and 9, are activated upon adenovirus infection to trigger 
production of proinflammatory mediators (Fejer et al. 2011). These include cytokines such as 
TNFa, IL-1a/b and IFNa/b, but also chemokines MCP-1, RANTES, IP-10, MIP-1a/b and IL-8 
(Hartman et al. 2008). Among first responders to these danger signals are dendritic cells, natural 
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killer cells, macrophages and neutrophils that help to control the infection by direct and indirect 
mechanisms (Thaci et al. 2011). Effective triggering of an adaptive immune response requires 
uptake of viral antigens via professional APCs, such as dendritic cells, and their cross-presentation 
on major histocompatibility complex (MHC) molecules to naïve T-cells (helper and cytotoxic) in 
the lymph node (Tacken et al. 2006). Development of an adaptive response takes approximately 
one week, and the development of a full humoral response (i.e. antibody-producing B-cells) 
against virus infection takes 2-4 weeks (Pesonen et al. 2010). 
The role of adenovirus-neutralizing antibodies (NAb) in gene therapy applications has been 
studied preclinically and in clinical trials with conflicting results. In some reports, pre-exisiting 
immunity has been associated with poor efficacy when intravenous adenovirus vectors have been 
administered repeatedly (Sterman et al. 2010). By contrast, pre-existing antiviral immunity 
appears to be an important part of the overall antitumor response, as seen in a preclinical 
adenovirus-permissive Syrian hamster model (Wang et al. 2016), and in patients treated with 
capsid-chimeric oncolytic adenovirus (Kanerva et al. 2013). Of note, Ad5/3 –based adenovirus 
can transduce distant brain metastases through the intravenous administration route despite the 
presence of neutralizing antibodies (Koski et al. 2015).  
Several approaches have been employed to protect virus particles from neutralization upon 
systemic administration. Cells of the immune system can be used as “carriers”, as shown with 
oncolytic reovirus in animal models (Ilett et al. 2011), and in cancer patients (Adair et al. 2012). 
Coating virus particles with polyethylene glycol (PEG) (O'Riordan et al. 1999) or albumin-
binding domains (Rojas et al. 2016) can shield the virus from pre-existing NAbs, but transduction 
efficiency can also be reduced (Hedley et al. 2006). 
Oncolytic viruses have been shown to elicit immunogenic cancer cell death (Guo et al. 2014). 
This should not be surprising, since virus infection produces abundant pathogen-associated 
molecular patterns (PAMPs) to be sensed by PRRs. In addition, viral oncolysis releases a natural 
repertoire of tumor-associated antigens (TAAs) for uptake by DCs (Bridle et al. 2010) (Figure 
1). Besides adenovirus, the following viruses have been shown to induce ICD: herpes simplex 
virus type 1 (Takasu et al. 2016), Newcastle disease virus (Koks et al. 2015, Schirrmacher 2015), 
measles virus (Donnelly et al. 2013), parvovirus (Angelova et al. 2014), and vaccinia virus 
(Parviainen et al. 2014). With regard to adenovirus, ICD induction has been confirmed with 
several virus constructs: Ad5/3-hTERT-E1A-hCD40L in EJ bladder carcinoma cells (Diaconu et 
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al. 2012), Ad5/3-D24-GMCSF in PC3-MM2 prostate cancer cells (Liikanen et al. 2013), and 
Ad5/3-D24-hTNFa in both of the above cell lines (Hirvinen et al. 2015). 
 
1.3.2.3 Preclinical animal models 
The study of oncolytic adenoviruses in vivo is limited to the available animal species that are 
permissive for human adenovirus replication. Unfortunately, the most widely used animals, i.e. 
immunocompetent mice, do not support replication (Ying et al. 2009). Immunodeficient mice 
with human xenograft tumors can, however, be utilized to evaluate adenovirus replication, but 
this scenario does not allow the assessment of host immune responses that are critically important 
for overall efficacy and safety. Mouse adenoviruses exist but their biology is far from human 
counterparts, and therefore are not of translational value (Lenaerts et al. 2005). Pigs have been 
reported to support Ad5 replication following intravenous administration (Jogler et al. 2006), and 
some porcine cell lines are permissive for certain serotypes (Griesche et al. 2008). However, the 
size of these animals inhibits their use as laboratory animals. 
Human group C adenovirus replicates in tissues of the cotton rat (Sigmodon hispidus) (Prince et 
al. 1993). Subsequently, syngeneic subcutaneous tumors of this animal have been treated with 
oncolytic adenoviruses (Toth et al. 2005, Steel et al. 2007). Also, cotton rats have been utilized as 
platforms for biodistribution and pharmacokinetic studies (Sonabend et al. 2009, Thaci et al. 
2012). Unfortunately, the cotton rat breeds poorly and is notoriously difficult to handle, which 
limits its usability as an experimental animal model (Niewiesk & Prince 2002). 
In addition to the cotton rat, Syrian (Golden) hamsters (Mesocricetus auratus) are permissive for 
human adenovirus (Thomas et al. 2006). To be precise, hamsters are “semi-permissive” as the 
replication efficiency is not directly equivalent to humans. Still, it is a significant improvement 
when compared with mice. As docile animals they are easy to handle and readily available from 
commercial breeders (Thomas et al. 2007). Therefore, many have taken advantage of this fully 
immunocompetent animal model in oncolytic adenovirus studies. For example, antitumor effects 
and safety of IL-12 or oncostatin M –coding viruses were evaluated in hamsters bearing orthotopic 
HapT1 pancreatic cancer tumors (Nistal-Villan et al. 2015, Poutou et al. 2015). The bioactivity of 
human GMCSF in hamster tissues was confirmed when the GMCSF-coding virus CGTG-102 (or 
Ad5/3-D24-GMCSF) was studied in hamsters with HapT1 tumors, in addition to replication 
kinetics and antitumor efficacy of this virus (Koski et al. 2010). Moreover, the GMCSF-coding 
virus Ad5-D24-GMCSF was able to not only eradicate HapT1 tumors, but induce tumor-specific 
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immunity as demonstrated by rechallenge experiments of cured animals (Cerullo et al. 2010a). 
Finally, Syrian hamsters are useful in preclinical biodistribution and toxicity studies when 
planning clinical trials with adenovirus (Matthews et al. 2009). 
 
1.3.2.4 Clinical experience 
The first oncolytic adenovirus taken into clinical trials, ONYX-015, was further modified and 
eventually accepted in China in 2005 (Oncorine) for nasopharyngeal carcinomas in combination 
with chemotherapy (Liang 2012). The results from Phase I and II trials with ONYX-015 showed 
that intratumoral, intravenous or hepatic artery administrations were all well-tolerated with no 
dose-limiting toxicities (Reid et al. 2002, Makower et al. 2003, Nemunaitis et al. 2007, Aiuti et 
al. 2007). Common adverse events were flu-like symptoms that were short-lived (Aiuti et al. 
2007). Interestingly, acute tumor enlargement followed by tumor regression was observed in the 
ONYX-015 trials (Reid et al. 2005). This therapy-mediated tumor swelling (or pseudoprogession) 
phenomenon has since been identified as a common theme in oncolytic virotherapy, and likely 
reflects the strong local inflammatory response that occurs after injection that masks the reduction 
in viable tumor cells (Hemminki 2014, Hemminki et al. 2014). 
The safety of a human telomerase reverse transcriptase promoter driven oncolytic adenovirus, 
Telomelysin, was studied in 16 patients with various advanced solid tumors (Nemunaitis et al. 
2010). This Phase I trial indicated that intratumoral virus injection was well-tolerated and 
suggestive evidence of efficacy was also observed. Another Phase I study confirmed the safety 
and feasibility of Ad5-D24-RGD in 21 patients with gynecologic malignancies (Kimball et al. 
2010). Treatment of 35 bladder cancer patients with GMCSF-encoding virus, CG0070, showed 
tolerable safety and a complete response rate of 48.6% (Burke et al. 2012). Recurrent ovarian 
cancer patients were treated intraperitoneally with a fiber-chimeric Ad5/3-D24 virus in a Phase I 
trial (Kim et al. 2013). 6 patients out of the 8 treated had stable disease and 2 patients had 
progressive disease, while adverse events were mild. Oncolytic adenovirus armed with cytosine 
deaminase/thymidine kinase transgenes has been used to treat prostate cancer patients with 
promising results (Freytag et al. 2007, Freytag et al. 2014). 
ONCOS-102 (or CGTG-102 or Ad5/3-D24-GMCSF) was recently studied in a Phase I trial with 
12 patients (Ranki et al. 2016). The patients received repeated intratumoral virus injections and 
daily low-dose cyclophosphamide. Virus treatment was well-tolerated, as no dose-limiting 
toxicities were observed. Based on positron emission tomography/computed tomography 
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(PET/CT) imaging, 40% had disease control, and interestingly 11 out of 12 patients showed 
prominent TIL infiltration post-treatment. Previously, CGTG-102 was used to treat patients with 
advanced solid tumors in the Advanced Therapy Access Program (ATAP) which was not a clinical 
trial, but a personalized treatment program under the Advanced Therapy Directive 
(EU/1394/2007) (Cerullo et al. 2010b, Koski et al. 2010, Bramante et al. 2014). Out of 290 
patients treated between 2007 and 2012, 115 received CGTG-102. The safety and efficacy profile 
in these patients was very similar to the 12 patients treated in the Phase I trial with CGTG-102. 
 
1.4  Non-replicating adenovirus vectors  
In addition to their use as oncolytics, adenoviruses can be utilized as vectors for transgene delivery 
into tumors. Early examples include a study where murine breast cancer was treated 
intratumorally with an adenovirus vector encoding the human IL-2 gene, which eliminated the 
tumors and induced protection against rechallenge (Addison et al. 1995). Similarly, a murine IL-
2 –coding vector was injected into murine mastocytoma tumors with a 75% cure rate (Cordier et 
al. 1995). Established fibrosarcoma tumors treated with IL-2 -coding adenovirus resulted in 
delayed tumor growth (Toloza et al. 1996). Mouse thyroid carcinoma tumors showed marked 
infiltration of CD4+ and CD8+ cells following injection with AdCMVmIL2, and protected cured 
animals from rechallenge (Zhang et al. 1998). In a Phase I clinical trial with breast cancer and 
melanoma patients, an E1/E3-deleted adenovirus encoding IL-2 (AdCAIL-2) was injected into 
subcutaneous lesions (Stewart et al. 1999). Clinical responses were not seen, but lymphocyte 
infiltration was observed in post-injection biopsies. Importantly, no circulating IL-2 was observed 
at any timepoint, indicating safety of the treatment. TG1024, another IL-2 –coding adenoviral 
vector, was used in a Phase I/II trial to treat advanced solid tumors and melanoma (Dummer et al. 
2008). In this trial, objective responses were only observed at the higher doses (above 3 x 1011 
VP). However, CD8+ lymphocyte infiltration was induced in injected lesions, and side effects 
were mild. 
Adenoviral vector carrying the TNFa gene was used to treat mouse colon adenocarcinoma MCA-
26 with intratumoral injections (Wright et al. 1999). As seen with IL-2 gene delivery, cured 
animals in this study developed protective immunity against rechallenge with the same tumor. 
TNFerade, a replication-deficient adenoviral vector for TNFa, has been studied in 8 clinical trials 
for various cancers (Kali 2015). In the most recent Phase I and Phase III trials TNFerade was 
administered alongside chemotherapy and radiation; the Phase I dose-escalation study indicated 
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the safety of the therapy (Seiwert et al. 2013), but antitumor efficacy in the Phase III study was 
absent despite the good safety profile seen before (Herman et al. 2013). 
TG1042, an adenovirus vector coding for interferon gamma (IFNg), has been studied in the 
treatment of cutaneous T- and B-cell lymphomas (Dummer et al. 2004, Dummer et al. 2010, 
Dreno et al. 2014). Treatments were well-tolerated and objective response rates were observed in 
50-85% of patients. Of note, CD8+ T-lymphocyte infiltration in the injected lesions correlated 
with clinical benefit (Accart et al. 2013). TG1042 has also been combined with adoptive transfer 
of TIL in metastatic melanoma patients (Khammari et al. 2015). In this clinical study, 18 stage 
IIIc/IV patients received repeated intralesional injections of TG1042 and two TIL infusions on 
days 1 and 29. Subcutaneous IL-2 was given after TIL infusions for 10 days. Overall objective 
response rate was 38.5% among the 13 patients evaluable, and the treatment was well-tolerated. 
Intratumoral administration of interferon beta (IFNb) –coding adenovirus vector caused tumor 
regressions in immunodeficient mice with established human xenograft tumors (Qin et al. 1998, 
Cao et al. 2001). Clinical studies with IFNb-coding viruses have been performed in patients with 
mesothelioma (Sterman et al. 2007, Sterman et al. 2010) and glioma (Chiocca et al. 2008) with 
good safety profiles (Dummer et al. 2004). 
Adp53, an adenovirus vector that restores the wild-type function of the tumor suppressor gene 
p53, was approved in China for the treatment of head and neck squamous cell carcinoma in 2004 
after clinical trials demonstrated safety and efficacy gains (Chen et al. 2014). Gene therapy for 
glioblastoma has been studied in a Phase III study with an adenoviral vector containing the herpes 
simplex virus thymidine kinase gene (sitimagene ceradenovec) in combination with ganciclovir 
(Westphal et al. 2013). 124 patients received the experimental treatment, whereas 126 received 
standard care; time to death was increased in the former but overall survival was not improved.  
Taken together, clinical studies with cytokine-coding adenoviral vectors have confirmed  the 
safety of the approach, but antitumor efficacy has remained rather modest. 
 
1.5 Tumor immunology and immunotherapy 
Tumors comprise a complex network of cellular and soluble factors that promote the growth and 
spread of the cancer, while hampering efficient recognition by the immune system in a process 
called cancer immunoediting (Dunn et al. 2002). The immunosuppressive tumor 
microenvironment (TME) represents a major barrier to tumor-reactive immune cells that have the 
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capacity to destroy tumor cells, but face a hostile environment. Overcoming immunosuppression 
is therefore one of the main goals of cancer immunotherapy. 
 
1.5.1 Cancer immunoediting and the tumor microenvironment 
The relationship between a developing tumor and the host immune system was originally 
postulated as “cancer immunosurveillance”, but has since been updated and termed “cancer 
immunoediting” to more accurately describe immune system-tumor interactions (Dunn et al. 
2004). Three phases can be distinguished, termed the “three E´s of cancer immunoediting:” 
Elimination, Equilibrium, and Escape.  
In the elimination phase, developing malignant cells are eradicated by innate and adaptive immune 
responses, i.e. through NK and T-cell activity, respectively. Tumor cells surviving the elimination 
phase enter the equilibrium phase, in which the immune system holds the tumor in a state of 
functional dormancy. Here, tumor cell variants that resist immune recognition evolve. Also, tumor 
cells induce immunosuppression by expression of programmed death ligand 1 (PD-L1). The 
tumor cytokine milieu in the equilibrium phase is a balance between tumor-promoting cytokines 
(IL-10, IL-23) and anti-tumor cytokines (IL-12, IFNg) (Mittal et al. 2014). 
In the escape phase, tumor cell variants that were selected in the previous phase can now grow 
and expand to a clinically detectable disease. Tumor escape consists of direct cellular interactions 
and indirect factors that disrupt the development of an antitumor immune response that could 
restrict tumor outgrowth. Tumor cells evade immune recognition by downregulating MHC Class 
I expression, but express survival-promoting molecules such as the anti-apoptotic bcl2 or 
resistance-increasing molecules like STAT3. Escape phase tumor cells also express molecules 
that mediate immunosuppression, e.g. PD-L1, indoleamine 2,3-dioxygenase 1 (IDO), tryptophan 
2,3-dioxygenase (TDO), and secrete angiogenesis-enhancing cytokines VEGF, IL-6, and TGFb. 
In addition, immunosuppressive cells such as M2 macrophages, myeloid-derived suppressor cells 
(MDSC) and regulatory T-cells (Treg) can express immunoregulatory molecules (arginase, iNOS, 
IDO) and immunosuppressive cytokines (IL-10, TGFb) (Mittal et al. 2014). 
 
1.5.2 Recombinant cytokines in cancer treatment 
Immunostimulatory cytokines have been used in cancer therapy based on their potent capacity to 
induce proliferation, differentiation and activation of immune cell subsets (Vacchelli et al. 2013). 
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To date, a handful of recombinant cytokines have been FDA-approved for the treatment of various 
cancers: IL-2, IFN-a2a, IFN-a2b, G-CSF, GMCSF and TNFa (Vacchelli et al. 2015). High-dose 
bolus IL-2 was approved for treatment of patients with renal cell carcinoma already in 1992, 
becoming the first immunotherapeutic cancer drug (Rosenberg 2014). 
Recombinant GMCSF has been evaluated for the treatment of renal cell carcinoma in multiple 
trials, but with modest results (Arellano & Lonial 2008). For melanoma, GMCSF has been 
administered together with IL-2, IFNa and chemotherapy with promising results, although 
systemic toxicity was also evident (Vaughan et al. 2000). In recent trials, GMCSF has been used 
in combination with radiotherapy (Golden et al. 2015) or with the cytotoxic T-lymphocyte-
associated protein 4 (CTLA4)-blocking monoclonal antibody ipilimumab (Luke et al. 2015). A 
27% response rate was observed in the former, whereas in the ipilimumab trial the response rate 
was 21%.  
TNFa is a powerful cytokine capable of inducing hemorrhagic necrosis (Carswell et al. 1975) and 
vasculature destruction in tumors (Watanabe et al. 1988). However, due to its toxicity profile, it 
is only used in isolated limb perfusion for treatment of soft-tissue sarcoma and melanoma 
metastases (Eggermont et al. 2003). In this role, TNFa is effective and safe as it can salvage limbs 
that would have otherwise undergone amputation in both of the aforementioned indications 
(Deroose et al. 2011, Deroose et al. 2012). 
Recombinant IFNg was studied in metastatic renal cell carcinoma patients who were administered 
IFNg-1b (n=91) or placebo (n=90) (Gleave et al. 1998). In this trial, no differences in efficacy 
were seen between the two treatment arms. Later, IFNg-1b was combined with 
carboplatin/paclitaxel chemotherapy for the treatment of advanced ovarian cancer patients in a 
phase III trial, but showed no improvement over chemotherapy alone (Alberts et al. 2008). 
As mentioned earlier, recombinant IL-2 was FDA-approved in the early 1990s for kidney cancer 
after clinical trials provided promising data (Lotze et al. 1986, Rosenberg et al. 1987). A clinical 
study performed in 270 patients with metastatic melanoma resulted in a 16% overall objective 
response rate, which prompted the approval of IL-2 for melanoma treatment in 1998 (Atkins et 
al. 1999). In the early trials, unexpected toxicities caused treatment-related deaths. This systemic 
IL-2 –related toxicity is caused by vascular leak syndrome (VLS), that is characterized by 
extravasation of fluids (via permeabilization of endothelial cells) into visceral organs that can 
result in organ failure (Baluna & Vitetta 1997). 
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In summary, cancer therapy with systemically administered recombinant cytokines can achieve 
some degree of antitumor activity that is, however, associated with severe toxicity. 
 
1.5.3 Immune checkpoint blockade 
Tumors express inhibitory molecules like PD-L1, which upon binding to its receptor programmed 
death 1 (PD1) on T-cells induces an inhibitory signal that results in reduced cytokine production, 
proliferation and cytotoxic activity (Freeman et al. 2000). In preclinical animal models blocking 
of the PD1/PD-L1 axis promotes antitumor activity (Curiel et al. 2003, Nomi et al. 2007). In 
humans, treatment with the checkpoint inhibiting anti-PD1 antibody, nivolumab, resulted in 
objective responses in patients with non-small-cell lung cancer (14 of 76 patients), melanoma (26 
of 94 patients), and renal cell cancer (9 of 33 patients) (Topalian et al. 2012). Another PD1 
inhibitor, pembrolizumab, has been used to treat advanced melanoma patients (Ribas et al. 2016), 
and Merkel-cell carcinoma patients (Nghiem et al. 2016). The overall objective response rate 
(ORR) in the melanoma trial was 33%. A 56% ORR was observed in the trial with Merkel-cell 
carcinoma patients. Pembrolizumab treatment in triple-negative breast cancer (TNBC) patients 
reached an ORR of 18.5%, with the median time to response being 17.9 weeks (Nanda et al. 2016), 
exemplifying the characteristic delayed response time of immunotherapies which warrants 
development of novel endpoint criteria (Hoos 2012).  
In addition to PD1/PD-L1, the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has been 
targeted by an inhibiting antibody, ipilimumab, with success in clinical trials (Weber et al. 2008, 
Robert et al. 2011). Altogether four checkpoint-inhibiting antibodies have been approved by the 
FDA: nivolumab, pembrolizumab, ipilimumab and atezolizumab (anti-PD-L1) (Pitt et al. 2016). 
Other immune checkpoint molecules being studied as targets for therapeutic intervention include 
lymphocyte-activated gene 3 (LAG-3), T cell immunoglobulin and mucin domain-containing 
molecule 3 (TIM-3), and B and T lymphocyte attenuator (BTLA) (Vilgelm et al. 2016). 
 
1.5.4 Adoptive cell therapies 
Pioneered by Dr. Steven Rosenberg at the Surgery Branch of the National Cancer Institute, 
adoptive cell therapy (ACT) aims to generate large numbers of tumor-reactive T-cells ex vivo that 
are subsequently administered back to patients with concurrent IL-2 infusions (Verdegaal 2016). 
Here, the three main approaches are summarized: unmodified tumor-infiltrating lymphocytes 
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(TIL), and the genetically engineered T-cell receptor-modified (TCR) and chimeric antigen 
receptor-modified (CAR) T-cells. 
 
1.5.4.1 Tumor-infiltrating lymphocytes 
Autologous lymphokine-activated killer (LAK) cells and systemic IL-2 infusions were used to 
treat metastatic cancer patients already in the mid-1980s (Rosenberg et al. 1985). Shortly after, 
tumors harboring tumor-specific lymphocyte populations were cultured and used therapeutically 
in a mouse model for colon adenocarcinoma (Rosenberg et al. 1986). In this study, the TIL were 
administered together with preconditioning lymphodepletion (cyclophosphamide) and systemic 
IL-2 infusions. Efficacy was impressive (50 to 100 times more effective than LAK) and provided 
the rationale to treat humans with adoptive transfer of TIL. 
Methods for obtaining sufficient amounts of TIL from tumor fragments have developed during 
the past three decades. In early methods, large metastatic lesions (around 3 cm) were resected and 
fragmented into microcultures in the presence of IL-2 for initial TIL outgrowth (Lee & Margolin 
2012). These TIL were then co-cultured with autologous tumor cells for assessment of IFNg 
release, indicating tumor-specific recognition by the TIL. Further propagation of the selected TIL 
populations was achieved by culturing them with high-dose IL-2, soluble anti-CD3 monoclonal 
antibody and irradiated feeder cells. This process of generating enough TIL for patient infusion 
took 5-6 weeks from biopsy. 
Several clinical trials have been performed with “selected TIL” in metastatic melanoma. ORRs 
have varied from 34% (Rosenberg et al. 1994) to 72% (Rosenberg et al. 2011), when 
lymphodepletion and total body irradiation (TBI) have been included in the regimen. However, 
the long ex vivo culture time presents a problem for the patient suffering from metastatic disease: 
rapid disease progression may prevent the patient from benefiting from TIL infusion. Also, it has 
been observed that those TIL that have spent a longer period of time in culture have shorter 
telomeres than younger TIL, thus limiting their proliferative capacity after adoptive transfer 
(Donia et al. 2011). These observations prompted the development of culture protocols that yield 
“young” TIL (Dudley et al. 2010) (Figure 3). The young TIL protocol omits the selection step 
and therefore shortens the culture time by several weeks, which increases the number of patients 
that can be included in the trial. The development of cell culture devices that specifically support 
optimal lymphocyte growth has improved T-cell production further (Vera et al. 2010, Jin et al. 
2012, Bajgain et al. 2014). 
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Clinical trials using young TIL have been performed in and outside the United States. The first 
one (at the Surgery Branch) enrolled 122 patients with metastatic melanoma, and eventually 56 
were treated (Dudley et al. 2010). The dropout rate was therefore 50%, still considerably less than 
with selected TIL. The ORR for treated patients was 54%. In this trial, the young TIL were 
enriched for CD8+ T-cells with the intention of avoiding Treg infusion. Later, the same group 
performed a trial comparing CD8+ enriched TIL and unselected “bulk” TIL (Dudley et al. 2013). 
101 patients were enrolled and 69 of them received TIL; 35 were treated with CD8+ enriched 
cells and 34 with unselected TIL. Interestingly, the ORR between the two arms (20% and 35%, 
respectively) was not significantly different, suggesting that TIL products containing CD4+ cells 
may play an important role in adoptive immunotherapy. 
At the MD Anderson Cancer Center, young TIL were administered to 31 patients with an ORR 
of 42% (Radvanyi et al. 2012). In Israel (Ella Institute), 32 patients were treated and the ORR was 
47% (Itzhaki et al. 2011). A similar study was performed later at the same site, with 80 enrolled 
patients of whom 57 were eventually treated with young TIL (Besser et al. 2013). The ORR for 
the treated patients was 40%. More recently, at the Herlev Hospital in Denmark, an ORR of 42% 
was achieved in 25 patients with melanoma (Andersen et al. 2016).  
The majority of TIL trials have been performed in patients with metastatic melanoma. However, 
the presence of TIL has been observed in almost all solid tumor types (Fridman et al. 2012). 
Several studies have demonstrated the feasibility of culturing tumor-reactive TIL from head and 
neck cancer (Junker et al. 2011), renal cell carcinoma (Markel et al. 2009, Baldan et al. 2015) and 
gastrointestinal cancer (Turcotte et al. 2013). In a recent clinical study, nine patients with 
metastatic cervical cancer were treated with human papillomavirus (HPV) –selected TIL, and 
three patients experienced objective responses (Stevanovic et al. 2015). Also, TIL therapy for 
ovarian cancer has shown promising results (Fujita et al. 1995). 
The rationale behind preconditioning lymphodepletion before TIL infusion is to “clear”  the host 
of factors that might impede the function of the transferred cells (Hershkovitz et al. 2010). This 
chemotherapy regimen typically consists of cyclophosphamide and fludarabine administered 
intravenously, sometimes combined with TBI. Endogenous suppressive cell compartments are 
targeted with preconditioning to relieve immunosuppression. Also, the removal of “cellular sinks” 
that deplete vital cytokines such as IL-7 and IL-15 has been shown to improve the efficacy of 
adoptively transferred T-cells (Gattinoni et al. 2005). In accord with this preclinical observation, 
patients treated with lymphodepletion prior to TIL infusion had elevated serum levels of these 
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cytokines (Dudley et al. 2008). In addition to preconditioning, TIL patients receive 
postconditioning IL-2 immediately after TIL infusion to support the transferred cells (Rosenberg 
2014). The systemic IL-2 administration is associated with severe but usually transient toxicity 
that requires specialized care (Schwartz et al. 2002). The importance of postconditioning IL-2 has 
been questioned, however, as it might in fact expand endogenous Tregs for a negative effect on 
efficacy (Yao et al. 2012). 
 
 
Figure 3. Adoptive cell therapy with “young” TIL. After tumor biopsy (1), the processed tumor 
material is cultured in IL-2 to enable initial TIL outgrowth (2). Further expansion is achieved by 
culturing the TIL in the presence of IL-2, anti-CD3 antibody and irradiated feeder cells (3). 
Following rapid expansion, the cells are administered back to the patient with concomitant IL-2 
infusions (4). 
 
1.5.4.2 T-cell receptor-engineered T-cells 
Tumor-infiltrating lymphocytes are not always available for expansion and sometimes the 
expansion phase itself can fail to produce enough TIL for infusion. By contrast, peripheral blood 
–derived  T-cells are easy to obtain and can be transduced with retroviruses coding for TAA-
specific T-cell receptors (TCR) (Bonini & Mondino 2015). TCRs are antigen receptors that 
recognize their target only when the antigen (i.e. processed peptide fragment) is bound to MHC 
Class I or II molecules. Adoptive cell therapy applications have so far been restricted to MHC 
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Class I –bound targets. The advantage of TCR-engineered cells, in addition to availability, is their 
ability to recognize tumor antigens derived from the entire protein composition of tumor cells, 
unlike CAR T-cells that require a surface antigen for recognition. On the other hand, the reliance 
on coreceptors (i.e. CD8) for TCR binding to MHC/peptide -complexes limits the effectiveness 
of target cell killing. Also, the expression of MHC Class I molecules is often downregulated on 
tumor cells, which may reduce the efficacy of TCR-engineered T-cells (Hicklin et al. 1999). 
The first TCR-engineered T-cells were generated in the mid-1980s for mouse studies (Dembic et 
al. 1986). Initial clinical studies in humans targeted melanoma antigen recognized by T cells 1 
(MART-1) (Duval et al. 2006). In this phase I dose-escalation trial, 15 patients received MART-
1 T-cells with a good safety profile and indications of tumor regressions. Later, 36 patients were 
treated with the MART-1 TCRs (and gp100 TCRs) in a larger trial (Johnson et al. 2009). Objective 
responses were seen in 30% of patients, but adverse events were also evident as “on-target, off-
tumor” effects; normal melanocytes of the inner ear and eye were attacked by the T-cells. 
More recently, cancer–testis antigen (CTA) family members have been targeted with TCR-
engineered T-cells in clinical trials: NY-ESO-1 (Robbins et al. 2011) and melanoma-associated 
antigen (MAGE) (Morgan et al. 2013). In the former, both metastatic melanoma and metastatic 
synovial cell sarcoma patients were treated, and clinical responses were observed in four (out of 
six) sarcoma patients and five (out of 11) melanoma patients without serious adverse events. In 
the latter trial, five out of nine patients experienced tumor regressions, but 2 patients died of 
neurological toxicity. This was due to the fact that MAGE-A3 –targeted TCRs also targeted 
MAGE-A12 expressed in the brain, which was not known at the time. In another MAGE-A3 TCR 
trial, the first two patients died of cardiotoxicity that was attributed to the “off-target, off-tumor” 
phenomenon as the TCRs exhibited cross-reactivity to a striated muscle protein, titin (Linette et 
al. 2013). 
TCR-engineered T-cells are a valuable tool in preclinical research. Several TCR-transgenic mouse 
strains are available from commercial breeders, and some are extensively used in cancer 
immunotherapy studies (Uckert & Schumacher 2009). Especially useful are artificial antigen-
targeting TCRs, such as the OT-I (Hogquist et al. 1994) and OT-II (Barnden et al. 1998) strains 
that target chicken ovalbumin. Tumor cell lines transduced to stably express ovalbumin, such as 
the murine B16.OVA melanoma, can be utilized in preclinical evaluation of novel 
immunotherapeutic approaches (Capasso et al. 2015, Tähtinen et al. 2015a, Tähtinen et al. 2015b). 
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1.5.4.3 Chimeric antigen receptor T-cells 
Chimeric antigen receptor T-cells (CAR-T) are genetically modified T-cells that recognize their 
target tumor antigens in an MHC-unrestricted manner (Ruella & June 2016). The chimeric 
receptor typically consists of a single-chain variable fragment (scFv) of a monoclonal antibody 
linked by a hinge and transmembrane domain to intracellular signaling/activation domains, i.e. 
immunoreceptor tyrosine-based activation motifs (ITAM) (Figure 4). Early constructs contained 
a single ITAM (Gross et al. 1989), while subsequent generations incorporated three ITAMs in the 
form of the TCR/CD3 zeta chain (CD3ζ) (Letourneur & Klausner 1991). The so-called second 
generation of CAR-T introduced an intracellular costimulatory domain, the cytoplasmic part of 
the CD28 receptor, in addition to the CD3ζ (Hombach et al. 2001). This additional domain 
improved T-cell activation upon binding to antigen (Maher et al. 2002). The third CAR-T 
generation has two costimulatory domains (e.g. 4-1BB or OX40 together with CD28) and the 
CD3ζ, providing even more potent responses (Milone et al. 2009, Hombach & Abken 2011). 
CAR-T targeting the pan-B-cell antigen CD19 have shown the most promising results in clinical 
trials: two children with B cell acute lymphoblastic leukemia (B-ALL) treated with anti-CD19 
CAR-T experienced complete remissions (Grupp et al. 2013), and in another trial all five B-ALL 
patients treated demonstrated rapid tumor eradication (Brentjens et al. 2013). More recently, a 
phase I trial performed in B-ALL patients resulted in a 70% complete response rate with 
manageable toxicities (Lee et al. 2015). Besides CD19, a variety of targets have been studied 
preclinically in the context of CAR-T therapy including MUC16 for ovarian cancer (Chekmasova 
et al. 2010), MUC1 for breast cancer (Wilkie et al. 2008), and EGFRvIII for glioblastoma (Miao 
et al. 2014).  
The remarkable clinical efficacy of CAR-T against hematological malignancies has not, however, 
been observed in solid tumors (Beatty & O'Hara 2016). Three main factors have been proposed 
to contribute to this phenomenon: 1) poor expansion and persistence of T-cells (Kershaw et al. 
2006), 2) insufficient T-cell trafficking (Kershaw et al. 2006), and 3) immunosuppressive tumor 
microenvironment (Moon et al. 2014). 
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Figure 4. Evolution of CAR-T constructs. In early constructs (1st generation), the mAb-derived 
scFv was linked to a transmembrane domain and a CD3ζ activation domain. 2nd and 3rd generation 
constructs include additional intracellular co-stimulatory domains (CD28, 4-1BB, OX-40) for 
enhanced T-cell activation. 
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2. AIMS OF THE STUDY 
 
 
1. To evaluate the antitumor efficacy and biological mechanisms of oncolytic 
adenovirotherapy combined with chemotherapy or adoptive cell therapy in preclinical 
rodent models for cancer (I-IV). 
 
2. To establish an immunocompetent and adenovirus-permissive Syrian hamster model for 
the study of adoptive TIL therapy combined with oncolytic adenovirus (II). 
 
3. To generate and characterize adenoviruses carrying the immunostimulatory cytokines 
IL-2 and TNFa for the enhancement of adoptive cell therapy (III-IV). 
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3. MATERIALS AND METHODS  
 
3.1 Viruses 
Murine cytokine-coding non-replicating adenovirus vectors were constructed by insertion of 
expression cassettes with cytokine genes into the multiple cloning site of the shuttle plasmid 
pDC315 (AdMax, Microbix Biosystems, Mississauga, Canada), which was then recombined with 
pBHGloxdelE13cre (AdMax) that contains the whole adenovirus genome. For the generation of 
the final virus constructs, rescue plasmids from the previous step were transfected to 293 cells. 
Viruses were propagated on 293 cells and purified with cesium chloride gradient centrifugation 
(Kanerva et al. 2002). The capsid-chimeric oncolytic adenoviruses used in Study IV were 
constructed by placing cytokine-transgenes into the E3 region of the adenovirus genome utilizing 
an adapted BAC-recombineering method (Warming et al. 2005, Ruzsics et al. 2006, Muck-Hausl 
et al. 2015). The resultant viruses were purified with cesium chloride gradient centrifugation, 
followed by VP-titering with OD260 reading, and Tissue Culture Infectious Dose (TCID50) assay 
to determine the number of infectious virus particles. The presence of exosome particles was not 
evaluated. All viruses used in the studies are listed in Table 1.  
 
Table 1. List of viruses used in the studies. 
Virus Replicating Transgene Reference 
Ad5/3-D24-GMCSF (aka CGTG-102)  Yes GMCSF Koski et 
al. 2010 
Ad5-D24 Yes  Kanerva 
et al. 2003 
Ad5Luc1 No  Kanerva 
et al. 2002 
Ad5-CMV-mTNFa No mTNFa III 
Ad5-CMV-mIL2 No mIL2 III 
Ad5-CMV-mIFNg No mIFNg III 
Ad5-CMV-mIFNb No mIFNb III 
Ad5/3-E2F-D24 Yes  IV 
Ad5/3-E2F-D24-hTNFa Yes hTNFa IV 
Ad5/3-E2F-D24-hIL2 Yes hIL2 IV 
Ad5/3-E2F-D24-hTNFa-IRES-hIL2 Yes hTNFa + hIL2 IV 
Vesicular stomatitis virus (VSV) strain 
M51 
Yes  Diallo et 
al. 2012 
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3.2 Cell lines 
All cell lines used in the studies were cultured in recommended conditions and are summarized 
in Table 2. 
 
Table 2. List of cell lines used in the studies. 
Cell line Species Description Source Used in 
DDT1-MF2 hamster leiomyosarcoma Prof. Wold1 I, II, IV 
HT-1080 human fibrosarcoma ATCC2 I 
SK-LMS-1 human leiomyosarcoma ATCC2 I 
RD human rhabdomyosarcoma ATCC2 I 
SW872 human liposarcoma ATCC2 I 
SW982 human synovial sarcoma ATCC2 I 
B16.OVA mouse melanoma Prof. Vile3 I, II, III 
HapT1 hamster pancreatic cancer DSMZ4 II, IV 
HMAM5 hamster breast cancer Dr. Mathis5 II 
PC1 hamster pancreatic cancer Prof. Wold1 II 
HaK hamster kidney cancer Prof. Wold1 II 
RPMI 1846 hamster melanoma ATCC2 II 
A549 human lung adenocarcinoma ATCC2 II, IV 
293 human embryonic kidney ATCC2 III 
L-929 mouse fibroblast ATCC2 III, IV 
CTLL-2 mouse T lymphocyte ATCC2 III, IV 
B16-Blue IFN-α/β mouse reporter melanoma InvivoGen6 III 
Panc1 human  pancreatic cancer ATCC2 IV 
SK-MEL-28 human  melanoma ATCC2 IV 
OVCAR-3 human  ovarian carcinoma ATCC2 IV 
SKOV3-Luc human  ovarian carcinoma Dr. Negrin7 IV 
     
1 Prof. William S.M. Wold (St. Louis University, School of Medicine, USA) 
2 American Type Culture Collection (Manassas, USA)  
3 Prof. Richard Vile (Mayo Clinic, USA)  
4 DSMZ (Braunschweig, Germany)  
5 Dr. Michael J. Mathis (Louisiana State University, USA)  
6 InvivoGen (San Diego, USA)  
7 Dr. Robert Negrin (Stanford Medical School, USA)   
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3.3 In vitro studies 
3.3.1 Chemotherapeutic agents (I) 
Ifosfamide (Holoxan®, Baxter Inc., Deerfield, USA) and 4-hydroperoxyifosfamide powder 
(Niomech GmbH, Bielefeld, Germany) were first reconstituted in sterile H2O, and subsequently 
diluted in growth media (for cell culture experiments) or sterile H2O if used in animal experiments. 
Doxorubicin (Medac GmbH, Wedel, Germany) was diluted in 0.9% sodium chloride (NaCl) 
solution for animal use, or in growth media if used in cell culture. 
 
3.3.2 Cell viability and co-culture experiments (I-IV) 
To determine cell viability after exposure to viruses, cells were seeded on 96-well plates at 1 x 
104 cells/well. Following overnight incubation, the cells were infected with varying viral 
particle/cell ratios (1-10 000). Viruses were diluted in growth medium (GM) containing 5% fetal 
bovine serum (FBS). After incubation at 37°C/5% CO2 for the indicated times, cell viability was 
measured using the [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium] (MTS) assay (Promega, Madison, USA). 
In co-culture experiments with adenovirus and chemotherapeutics, target cells were seeded and 
cultured overnight as described above, and infected with virus (1000 VP/cell) and 4-
hydroperoxyifosfamide (3000 ng/ml) and/or doxorubicin (100 ng/ml) simultaneously. 14 days 
after incubation, cell viability was determined by MTS. 
In order to evaluate the cell killing capacity of hamster TIL, effector-to-target assays (E/T) were 
performed with autologous tumor cells, other hamster tumor cells or human A549 cells by seeding 
96-well plates with target cells at 1 x 104 cells/well, followed by the addition of TIL (as effectors) 
at different E/T ratios. After 24 hours of incubation, target cell viability was determined by MTS.  
For the assessment of cell killing synergy between Ad5-D24 and HapT1 TIL, target cells seeded 
the day before were first infected with 100 VP/cell of Ad5-D24 and culture for 3 days before 
adding HapT1 TIL at a 2:1 E/T ratio. 24 hours after co-culture the viability of target cells was 
determined by MTS. In Study IV, synergy between viruses and TIL was examined by infecting 
HapT1 cells with viruses (5000 VP/cell) for 72 hours before adding 2.5 x 104 TIL. Cell viability 
was determined 24 hours later by MTS. 
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3.3.3 Quantitative PCR from tumor cell lines (I) 
Total DNA was extracted (with QIAamp DNA Mini Kit, Qiagen, Valencia, USA) from DDT1-
MF2 cell culture monolayers to perform qPCR after exposure to adenovirus, with or without 
chemotherapy. The target was the adenoviral E4 gene while hamster GAPDH served as the 
housekeeping gene, as described previously (Koski et al. 2010). In studies with human STS cell 
lines, monolayers were harvested identically and analyzed for E4 while human beta-actin served 
as the housekeeping gene. All primer and probe sequences are summarized in Table 3. 
 
Table 3. Primers and probes used in quantitative PCR. 
Target Type Sequence 5´ to 3´ 
Adenovirus 
E4 Forward primer GGAGTGCGCCGAGACAAC 
 Reverse primer ACTACGTCCGGCGTTCCAT 
 Probe TGGCATGACACTACGACCAACACGATCT 
Hamster 
GAPDH Forward primer CACCGAGGACCAGGTTGTCT 
 Reverse primer CATACCAGGAGATGAGCTTTACGA 
 Probe CAAGAGTGACTCCCACTCTTCCACCTTTGA 
Human beta-
actin Forward primer TCACCCACACTGTGCCCATCT 
 Reverse primer GTGAGGATCTTCATGAGGTAGTCAGTC 
 Probe ATGCCCTCCCCCATGCCATCCTGCGT 
 
 
3.3.4 Immunogenic cancer cell death (I) 
The capability of oncolytic adenovirus to induce immunogenic cell death of cancer cells in 
combination with chemotherapy was studied in vitro by infecting hamster cells (DDT1-MF2) with 
Ad5/3-D24-GMCSF (1000 VP/cell) and doxorubicin (5 ng/ml) plus 4-hydroperoxyifosfamide 
(150 ng/ml). Calreticulin exposure was assessed 12 hours later by staining the cells first with anti-
calreticulin antibody (ab2907, Abcam, Cambridge, UK), followed by Alexa-Fluor® 488 -
conjugated secondary antibody staining (A21202, Invitrogen, San Diego, USA). BD Accuri C6 
flow cytometer (BD Biosciences, San Jose, USA) was used for analysis of stained cells. The cell 
culture supernatants were analyzed for HMGB1 and ATP secretion using HMGB1 ELISA kit 
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(ST51011, IBL International, Hamburg, Germany) and ATP Determination kit (A22066, 
Molecular Probes, Invitrogen) 24 and 48 hours after treatment, respectively. Induction of ICD in 
human STS cells was studied similarly, with the exception of using a virus concentration of 100 
VP/cell and only doxorubicin as chemotherapeutic.  
 
3.3.5 Blocking experiments (II) 
To evaluate the role of MHC-restriction in target cell killing of hamster TIL, tumor cells plated 
on 96-well plates were pre-incubated for 2 hours with cross-reactive anti-MHC-I monoclonal 
antibody (50 μg/ml) (clone 2G5, Novus Biologicals, Littleton, USA) or isotype control (mouse 
IgG2b, Novus Biologicals) before TIL effector cells were added. Cell viability was determined 
24 hours later by MTS. To confirm that the anti-MHC-I mAb indeed has blocking capability, 
B16.OVA cells were pre-incubated with the mAb (or isotype control mAb) before OVA-specific 
CD8-enriched OT-I T-cells were added, and target cell viability was determined as previously. 
 
3.3.6 Cytokine expression (III, IV) 
293 cells were used to evaluate cytokine production from non-replicating adenovirus vectors 
coding for murine cytokines. Supernatants from virus-infected cell cultures (100 VP/cell) were 
collected after 48 hours of incubation and analyzed with ELISA kits for mIFNb (PBL 
InterferonSource, Piscataway, USA), mIFNg (Abcam), mIL-2 and mTNFa (IBL International). 
In vitro cytokine expression from oncolytic viruses coding for human IL-2 and human TNFa were 
studied in HapT1, DDT1-MF2, SKOV3-Luc and A549 cell culture supernatants after a 72 hour 
infection period. Detection was performed with CBA Flex Sets (558270 and 558273, BD 
Biosciences) together with BD Cytometric Bead Array Human Soluble Protein Master Buffer Kit, 
and analyzed with BD Accuri C6. 
 
3.3.7 Cytokine functionality (III, IV) 
To confirm the biological functionality of the virus-encoded murine cytokines, standard bioassays 
were performed on supernatants collected from virus-infected 293 cells. Before assaying, the 
supernatants were filtered through 0.02 μm inorganic membrane filters (Whatman, Maidstone, 
UK) to prevent virus carryover. In all functionality assays,  recombinant cytokines from a 
commercial vendor were used as positive controls (R&D Systems, Minneapolis, USA), and 
Ad5luc1 served as the negative control for the cytokine-coding viruses (Kanerva et al. 2002). 
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For the assessment of virus-derived mIL-2 bioactivity, the IL-2-dependent non-adherent CTLL-2 
cell line was used. Filtered supernatant was added on CTLL-2 cells on 96-well plates (2.5 x 104 
cells/well) and incubated for 48 hours before determining cell viability by MTS. The functionality 
of mTNFa was confirmed by co-culturing filtered supernatant with TNFa-sensitive mouse L-929 
fibroblast cells (1 x 104 cells/well, 96-well plate). After 24 hours of incubation, cell viability was 
determined by MTS. The bioassay for mIFNg is a “protection assay”, i.e. if bioactive mIFNg is 
present, L-929 cells are protected from   vesicular stomatitis virus (VSV) infection. To this end, 
L-929 cells were pre-incubated with filtered supernatant for 6 hours before exposure to 1 x 104 
VP/well of VSV strain M51 (kindly provided by Dr. Markus Vähä-Koskela, University of 
Helsinki). Cell viability was determined 96 hours post-infection. For mIFNb bioactivity, 
commercial B16-Blue IFN-α/β murine type I IFNs sensor cells (InvivoGen, San Diego, USA) 
were used according to manufacturer´s instructions. Human cytokines hIL-2 and hTNFa (from 
viruses constructed in Study IV) were confirmed to be bioactive with CTLL-2 and L-929 cells, 
respectively. 
 
3.4 In vivo studies 
3.4.1 Syrian hamster sarcoma model (I) 
For evaluation of antitumor efficacy of the adenovirus/chemotherapy combination, Syrian 
(Golden) hamsters obtained from Harlan Laboratories (Indianapolis, USA) were implanted with 
DDT1-MF2 leiomyosarcoma cells subcutaneously into both flanks of each animal (5 x 106 
cells/flank). In the first experiment (with doxorubicin and ifosfamide) male hamsters were 
anesthetized for all experimental procedures with a mixture of Ketalar® (ketamine) 80 mg/kg + 
Rompun vet® (xylazine) 5 mg/kg administered intraperitoneally. After reaching 5 mm in 
diameter, intratumoral virus injections (2.25 x 108 VP/tumor) and intraperitoneal chemotherapy 
injections (doxorubicin 1 mg/kg, ifosfamide 30 mg/kg) were started and repeated every 3 days 
after that. Animals in the control group received PBS vehicle only. Digital calipers were used to 
measure tumor growth throughout the experiment. In the second experiment where only 
doxorubicin was given together with adenovirus, all animals were anesthetized with isoflurane 
before procedures. Virus (2.25 x 108 VP/tumor) and doxorubicin (1.25 mg/kg) were administered 
every other day. 
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3.4.2 Oncolytic adenovirus and chemotherapy in the B16.OVA model (I) 
To gain deeper understanding of the biological mechanisms behind therapeutic synergy, the 
B16.OVA murine melanoma model was employed. Female C57BL/6 mice (Harlan Laboratories) 
were implanted subcutaneously with 2.5 x 106 B16.OVA cells into both flanks. 5 mm diameter 
tumors were injected intratumorally with 4.5 x 109 VP/tumor every 3 days, and chemotherapy 
(doxorubicin 1 mg/kg, ifosfamide 30 mg/kg) was administered intraperitoneally every 3 days. 
Endpoint tumors and spleens were collected for flow cytometric analyses. 
 
3.4.3 Quantitative PCR from tumors (I) 
To perform qPCR from DDT1-MF2 tumors, tumor fragments were excised from euthanized 
hamsters and snap-frozen at -80°C for storage. Total DNA was extracted by first digesting tumor 
samples overnight with proteinase K in tissue lysis buffer ATL (Qiagen), followed by QIAamp 
DNA Mini Kit (Qiagen) extraction protocol. Quantification of adenoviral E4 (normalized to 
hamster GAPDH) was performed with primers and probes described in Table 3.  
 
3.4.4 Human soft-tissue sarcoma xenograft model (I) 
For the assessment of antitumor efficacy against STS tumors of human origin, female NMRI nude 
mice (from Harlan Laboratories) were implanted with 5 x 106 HT-1080 fibrosarcoma cells into 
both flanks under isoflurane anesthesia. After reaching 5 mm in diameter, the tumors were injected 
with 1 x 108 VP/tumor of virus on days 1, 4, 8 and 15. Chemotherapy, i.e. doxorubicin, was given 
intraperitoneally on days 1, 8 and 15 with a dose of 2 mg/kg. Control animals received vehicle 
only. Tumor sizes were measured with digital calipers every 3 days. 
 
3.4.5 Histopathology (I, IV) 
For histopathological analysis tumors, spleen, liver, heart, lung and kidneys were collected from 
hamsters and fixed in 10% formalin for 48-72 hours before transfer into 70% ethanol for storage. 
4 μm sections were cut from paraffin-wax embedded organ samples and stained with hematoxylin 
and eosin. Histological changes were evaluated by independent veterinary pathologists, and 
tumors that lacked neoplastic cells were considered cured. 
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3.4.6 TIL culture (II, IV) 
For initiation of TIL culture, Syrian hamsters were first implanted with tumors subcutaneously 
and allowed to develop until 1 cm in diameter. In Study II, the excised tumors were processed 
into small fragments (1-3 mm3) and cultured on 24-well plates (1 fragment/well). The RPMI-1640 
–based culture medium contained 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, 1% 
L-glutamine, 15 mM HEPES, 50 μM 2-mercaptoethanol, 1 mM Na-pyruvate and 6000 IU/ml 
human IL-2 (hIL-2) (PeproTech, Rocky Hill, USA). After 5 days of initial culture, 50% of the 
medium was removed and replaced with fresh medium. Medium renewal was repeated every 2 
days after Day 5. On Day 10, the TIL culture wells that contained visible lymphocyte growth were 
pooled for further experiments in vivo or in vitro. 
In Study IV, tumors for initiation of TIL culture were implanted and processed similarly, but the 
tumor fragments were cultured in gas-permeable G-Rex10 flasks (80040S, Wilson Wolf, New 
Brighton, USA) in the presence of 3000 IU/ml hIL-2 (PeproTech). On Day 5, 50% of the medium 
was replaced with fresh medium containing 1 μg/ml Concanavalin A (C0412, Sigma-Aldrich, St. 
Louis, USA). Medium renewal was repeated every 2 days until Day 10 when TIL were collected 
and used in animal experiments or cell killing assays. 
 
3.4.7 Adoptive TIL transfer and virus treatments (II, IV) 
In Study II, established HapT1 tumors were treated with Ad5-D24 (1 x 107 VP/tumor) and on the 
following day HapT1 TIL were injected intratumorally (1.5 x 106 TIL/tumor). Virus treatment 
was repeated on Day 8. In Study IV, the hamsters were given virus injections on Days 1, 4, 8, 13 
and 19 (1 x 109 VP/tumor). HapT1 TIL were administered on Day 2 intratumorally (4 x 105 
TIL/tumor). In the repeat experiment, only the virus dose was altered (1 x 108 VP/tumor on Days 
1 and 8). Animals cured of tumors in the first experiment were rested for 2 weeks before being 
subjected to tumor rechallenge with the same tumor (HapT1) or another tumor type (DDT1-MF2). 
 
3.4.8 Transgene expression (III, IV) 
Expression of transgenes in vivo was evaluated in the B16.OVA model in Study III. C57BL/6 
mice (Harlan Laboratories) were implanted with B16.OVA tumors and injected with 1 x 109 VP 
of cytokine-coding adenoviruses. Tumors and serum were collected 72 hours later by snap-
freezing at -80°C. After homogenization of the tumors, murine cytokine concentrations were 
measured with CBA Flex Sets (BD) and normalized to total protein content. 
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In Study IV, Syrian hamsters bearing HapT1 tumors were utilized to determine in vivo human 
cytokine expression from the newly constructed oncolytic adenoviruses. To this end, 1 x 108 VP 
were injected into HapT1 tumors, and 48 hours later the tumors were collected along with serum. 
CBA Flex Sets for human IL-2 and TNFa were used to quantify cytokine levels in tumors and 
serum after normalization to total protein content. 
 
3.4.9 Chemokine expression (III) 
CBA Flex Sets were used to determine chemokine levels in B16.OVA tumors after treatment with 
adenoviruses and OT-I cells. 7 days after injection, snap-frozen tumors were homogenized and 
analyzed for RANTES, MCP1, MIP-1a, MIP-1b, MIG and I-TAC normalized to total protein 
content. 
 
3.4.10 Adoptive OT-I transfer (III) 
Culture and expansion of OT-I T-cells for adoptive transfer was performed by collecting spleens 
of OT-I TCR transgenic mice (The Jackson Laboratory, Bar Harbor, USA), and culturing the 
splenocytes in mIL-2 (160 ng/ml, R&D Systems) and anti-mouse CD3e antibody (300 ng/ml, 
clone 145-2C11, eBioscience, San Diego, USA). After 3 days in culture, CD8-enrichment was 
performed with CD8a+ T Cell Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany). T-
cell expansion was continued for another 7 days in the presence of mIL-2 and anti-CD3e. 
Adoptive transfer of expanded OT-I CD8+ T-cells was performed by injecting 1.5 x 106 cells (in 
a volume of 100 μl) intraperitoneally into B16.OVA tumor-bearing mice. 
 
3.4.11 OT-I radiolabelling and SPECT/CT imaging (III) 
To follow the fate of adoptively transferred OT-I T-cells, we labelled 6 x 106 CD8+ enriched cells 
with 111In-oxine and injected them into tumor-bearing and adenovirus-injected mice 
intraperitoneally (5.98 ± 0.53 MBq/animal). A preclinical four-headed gamma camera with 
integrated CT system (nanoSPECT/CT, Bioscan Inc., USA) was used to image the mice 24, 48 
and 96 hours after cell/virus treatment.  
 
3.4.12 Orthotopic SCID mouse model of ovarian cancer (IV) 
To investigate the antitumor effects of cytokine-coding oncolytic adenoviruses against human 
tumors, immunocompromised female CB-17 SCID mice (Janvier Labs, Saint Berthevin, France) 
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were implanted with 5 x 106 SKOV3-Luc luciferase-coding ovarian cancer cells intraperitoneally. 
In a dose-finding pilot experiment the mice received 1 x 105, 1 x 107 or 1 x 109 VP of Ad5/3-E2F-
d24-hTNFa-IRES-hIL2 in 300 μl of PBS intraperitoneally. Bioluminescent imaging was 
performed by administering D-luciferin (3 mg in 100 μl PBS, bc219, Synchem, Felsberg, 
Germany) 8 minute before placing the animals in the IVIS 100 imaging device (Xenogen, 
Alameda, USA). In the full-scale experiment, 1 x 109 VP of each virus in 300 μl PBS was given 
intraperitoneally to tumor-bearing mice. IVIS imaging was performed once per week. 
 
3.4.13 Splenocyte proliferation (IV) 
Splenocytes proliferation ex vivo was assessed by culturing splenocytes for 72 hours before 
counting the cells with BD Accuri C6. Samples (i.e. spleens from individual animals) were pooled 
within a treatment group before performing the assay. 
 
3.4.14 Flow cytometry (I-IV) 
Tissues in all Studies were first processed into single-cell suspensions by passing them through 
40-70 μm cell strainers. After overnight culture at 37°C, cell suspensions were frozen and stored 
at -80°C or -140°C. For flow cytometric analyses, thawed samples were stained with fluorescently 
labelled antibodies (Table 4) for 30 minutes at 4°C before analysis with BD Accuri C6. 
 
Table 4. List of antibodies used in flow cytometric analyses. 
Antibody Host species Supplier Used in 
CD80-PerCP-Cy5.5 armenian hamster BD I 
CD8a-PE  rat BD I 
CD3-APC armenian hamster BD I, III 
CD86-PE rat BD I, III 
CD11c-FITC armenian hamster BD I, III 
MHC Class II-FITC  mouse eBioscience II, IV 
CD4-APC  rat eBioscience II, IV 
CD8b-PE  mouse eBioscience II, IV 
CD8b-FITC rat eBioscience III 
CD8a-APC rat eBioscience III 
PD-1-PeCy7 armenian hamster eBioscience III 
NK1.1-FITC mouse eBioscience III 
CD19-PE rat eBioscience III 
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CD25-PE rat eBioscience III 
Foxp3-APC rat eBioscience III 
CD69-PeCy7 armenian hamster eBioscience III 
F4/80-APC rat eBioscience III 
CD3-PeCy7 rat BD III 
CD4-PerCP.Cy5.5 rat BD III 
CD11b-PerCP-Cy5.5 rat BD III 
Gr-1-FITC rat BD III 
 
 
3.5 Statistical analyses 
In all Studies, statistical analyses were performed with SPSS version 21 or 22 (SPSS IBM, New 
York, USA) and GraphPad Prism 6 (GraphPad Software Inc., San Diego, USA). When applicable 
(i.e. no missing values present), repeated measures ANOVA was performed on log-transformed 
tumor volume data. For estimation of statistical differences between groups in other cases, non-
parametric Mann-Whitney test, two-tailed Student´t t-test and linear mixed-effects model were 
used. P-values of <0.05 were considered significant in all Studies. In Study I, synergy between 
adenovirus and chemotherapy was evaluated with an adapted Webb method (Webb 1963), named 
FTV (fractional tumor volume). Ratios above 1 indicate synergistic interactions, whereas ratios 
below 1 indicate less than additive effects. 
 
3.6 Ethical considerations 
All animal protocols were reviewed and approved by the Experimental Animal Committee of the 
University of Helsinki and the Provincial Government of Southern Finland 
(ESAVI/7759/04.10.07/2013). Animals were humanely euthanized when tumor size exceeded the 
maximum acceptable size or when any signs of pain or distress were evident. 
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4. RESULTS AND DISCUSSION  
 
4.1 In vitro studies with doxorubicin/ifosfamide and oncolytic adenovirus Ad5/3-D24-
GMCSF (I)  
The efficacy of oncolytic adenoviruses as single agents to treat advanced cancer has been 
unimpressive (Rosewell Shaw & Suzuki 2016). Chemotherapeutic regimens have suffered from 
the same problem, as only a portion of patients benefit from treatment and for soft-tissue sarcoma 
(STS) specifically the response rates with preferred first-line chemotherapeutics doxorubicin and 
ifosfamide are modest (Clark et al. 2005, Reed & Altiok 2011, Quesada & Amato 2012). 
Therefore, in Study I we set out to study the combination of these two treatment modalities for 
possible synergistic interactions that could yield a translationally relevant combination therapy 
approach for STS.  
First, the in vitro effects of the oncolytic adenovirus Ad5/3-D24-GMCSF (aka CGTG-102) 
together with doxorubicin and 4-hydroperoxyifosfamide (the active metabolite of ifosfamide) 
were studied in cytotoxicity and immunogenic cell death (ICD) assays with STS cells. Infection 
of DDT1-MF2 Syrian hamster leiomyosarcoma cells with Ad5/3-D24-GMCSF resulted in 
significant upregulation of cell-surface calreticulin exposure, that was further enhanced with the 
addition of doxorubicin/4-hydroperoxyifosfamide chemotherapy (Figure 1a, Study I). The same 
trend was observed for the two other ICD markers, HMGB1 and ATP secretion (Figure 1b-c, 
Study I). The immunogenic cell death status of human STS cells exposed to adenovirus and 
chemotherapeutics showed less clear results when compared with the hamster DDT1-MF2 cells 
(Suppl. Figure S2-S4, Study I), although a similar trend for additivity was observed with HT-1080 
fibrosarcoma cells.  
We then studied the effect of chemotherapy on adenoviral replication efficiency and observed an 
increase when doxorubicin/4-hydroperoxyifosfamide were present in the cell culture (Figure 1d, 
Study I). Moreover, hamster STS cell killing was enhanced with the combination of Ad5/3-D24-
GMCSF and doxorubicin/4-hydroperoxyifosfamide (Figure 1e, Study I). When human STS cell 
lines were studied for adenovirus replication kinetics in the presence of doxorubicin, we showed 
that in 4 out of 5 cell lines the efficiency of virus replication was improved during the 96 hour 
incubation period (Figure 4, Study I).  
Several oncolytic viruses have the ability to induce immunogenic cancer cell death (Workenhe & 
Mossman 2014). We have shown this with different adenovirus constructs before (Diaconu et al. 
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2012, Liikanen et al. 2013, Hirvinen et al. 2015). Our results from Study I are in line with a recent 
report (with the same adenovirus construct Ad5/3-D24-GMCSF) where ICD was induced in 
mesothelioma cell lines in combination with chemotherapy (Kuryk et al. 2016). An intriguing line 
of investigation involving the induction of ICD in vivo was not pursued in Study I due to feasibility 
issues. ICD is relatively easy to assess in vitro in the homogeneous “tumor cells on a plate” setting, 
whereas the heterogeneity of established tumors makes it impossible to identify the specific source 
of secreted ATP/HMGB1. This highly relevant topic of in vivo ICD should be studied further if 
more advanced methods can be developed. 
With regard to synergistic interactions between oncolytic viruses and doxorubicin in vitro, our 
observations are similar to studies performed with measles virus (Weiland et al. 2014), herpes 
simplex virus (Bolyard et al. 2014), coxsackievirus (Skelding et al. 2012), vesicular stomatitis 
virus (Schache et al. 2009), and adenovirus (Osaki et al. 2016). The mechanism behind synergy 
was attributed to enhanced virus replication in our study which, interestingly, was also observed 
in the report with oncolytic measles virus (Weiland et al. 2014). In the latter, induction of tumor 
cell senescence by doxorubicin was shown to promote viral replication.  
 
4.2 In vivo antitumor efficacy is enhanced with oncolytic adenovirus and chemotherapy 
combinations (I)  
Results obtained from in vitro studies with Ad5/3-D24-GMCSF and doxorubicin-based 
chemotherapy provided strong rationale for further experiments in vivo. As an immunocompetent 
animal model we used the Syrian hamster. Established DDT1-MF2 tumors were treated with the 
combination of doxorubicin/ifosfamide and Ad5/3-D24-GMCSF or with the single agents every 
3 days (Figure 2a-b, Study I). Antitumor efficacy was greatly enhanced with the combination 
approach against this highly aggressive tumor model. Importantly, we evaluated combination 
effects with the Fractional Tumor Volume method (FTV), that is derived from the Webb method 
(Webb 1963), to provide a more accurate assessment of the nature of the interaction between virus 
and chemotherapy. With the FTV approach we were able to confirm that the combination of 
Ad5/3-D24-GMCSF and doxorubicin/ifosfamide was indeed synergistic in the hamster model 
(Figure 2c, Study I).  
Prompted by the EORTC 62012 Phase III trial result (Judson et al. 2014), which indicated that 
doxorubicin plus ifosfamide was not superior to doxorubicin alone, we conducted a combination 
study in Syrian hamsters with Ad5/3-D24-GMCSF and doxorubicin alone. This experiment 
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revealed that the virus combined with doxorubicin was not superior to doxorubicin alone, although 
both were superior to mock (Figure 3a, Study I). Interestingly, when the tumors were collected at 
the end of the experiment and analyzed for adenoviral E4 gene copies by qPCR we observed a 
significant increase in E4 copy numbers if the animals were treated with doxorubicin plus Ad5/3-
D24-GMCSF as compared with virus alone (Figure 3b, Study I). This result was in line with our 
in vitro observations where chemotherapy enhanced virus replication in STS cells. 
NMRI nude mice were used to examine the antitumor effects of Ad5/3-D24-GMCSF and 
doxorubicin against STS of human origin. HT-1080 fibrosarcoma xenografts could be very 
effectively treated with the combination approach as most tumors (15 out of 16) were completely 
eradicated in the virus plus chemotherapy group (Figure 5a-b, Study I). The interaction was 
synergistic, as confirmed by the FTV method (Figure 5c, Study I). 
The role of chemotherapy in modulating host leukocyte number and function could be studied in 
more detail in Syrian hamsters if more reagents emerge. Cyclophosphamide has already been 
shown to selectively deplete Tregs (Ghiringhelli et al. 2007). Since ifosfamide bears significant 
structural resemblance to cyclophosphamide, it is possible that ifosfamide has similar effects on 
Tregs. However, this has not been studied in preclinical or clinical settings. Recently it was 
discovered that doxorubicin selectively eliminates immunosuppressive MDSC in spleen, blood 
and tumor ((Alizadeh et al. 2014). Again, this is not an aspect that can be studied in hamsters due 
to lack of reagents but remains an interesting topic for future research. Taken together, the 
combinatorial use of ifosfamide and doxorubicin in immunocompetent tumor models could render 
the tumor microenvironment less immunosuppressive, thus facilitating antitumor T-cell 
responses. 
In conclusion, the combination of oncolytic adenovirus and doxorubicin-based chemotherapy 
represents an effective approach for treatment of soft-tissue sarcoma. Our results suggest that 
synergy between the two agents comprises two nonmutually exclusive mechanisms: induction of 
immunogenic cell death and enhancement of adenovirus replication. 
 
4.3 Tumor-infiltrating lymphocytes (TIL) can be cultured ex vivo from syngeneic Syrian 
hamster tumors (II)  
The study of adoptive cell therapies (ACT) in the preclinical setting has been limited to the use of 
mice. To broaden the repertoire of preclinical animal models for ACT and to establish an 
adenovirus-permissive model suitable for oncolytic virotherapy studies combined with ACT, we 
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set out to culture and characterize tumor-infiltrating lymphocytes (TIL) of the Syrian hamster in 
Study II. 
Several implantable tumor cell lines were available for this study. These syngeneic cells 
represented various histologies and could successfully be grown in hamsters subcutaneously. 
Flow cytometric immunophenotyping studies revealed that the tumors contained varying amounts 
of infiltrating CD4+ and CD8+ T-cells (Figure 1a-f, Study II). The most abundant T-cell type was 
CD4 in all six tumor types studied. CD8+ T-cells were found in 4 out of 6 tumors. When the 
tumors were excised, cut into small fragments and cultured in high-dose IL-2, we observed 
lymphocyte expansion around the fragments within 5 days (Figure 2a-f, Study II). After 10 days 
of ex vivo culture the lymphocytes were collected and used in effector-to-target assays to examine 
the cell killing capability of the cultured TIL (Figure 3a-f, Study II). HapT1 pancreatic cancer-
derived TIL were able to kill autologous HapT1 cells specifically while sparing non-related 
hamster tumor cells (DDT1-MF2) or human A549 cells. The same applied for TIL cultured from 
RPMI 1846 melanoma tumors. TIL from the other 4 tumor types exhibited non-specific cell 
killing properties. 
In further experiments with HapT1 and RPMI 1846 TIL we evaluated the effect of MHC Class I 
blocking on the cytolytic activity of TIL (Figure 4a-b, Study II). Interestingly, the cell killing 
ability of RPMI 1846 TIL was completely abolished by MHC blocking which indicates that tumor 
cell killing in the TIL population is mediated by cytotoxic T lymphocytes (CTL). On the contrary, 
cytotoxicity of TIL from HapT1 was only partially abrogated by blocking. Since HapT1 TIL cell 
killing was still specific to HapT1 tumor cells, the presence of NK cells seemed counterintuitive. 
Therefore, we hypothesized that CD4+ T-cells in the TIL population could have gained cytotoxic 
properties which was also supported by the observation that HapT1 cells expressed MHC Class 
II molecules (Suppl. Figure S1, Study II). 
The role of CD4+ T-cells in adoptive immunotherapy (and tumor immunology in general) 
warrants further investigation. Clinical trials have been performed where adoptively transferred 
TIL preparations have consisted of predominantly CD4+ T-cells and yet the patients respond well 
(Wu et al. 2012). CD4+ T-cells have an important role in supporting CD8+ T-cell function and 
thus it would seem preferable to include CD4+ T-cells in TIL preparations (Kamphorst & Ahmed 
2013). In our preclinical hamster model the TIL administered to tumor-bearing animals comprised 
15% CD4+ T-cells and 10% CD8+ T-cells. Furthermore, these TIL were considered “young” 
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since the ex vivo culture period was only 10 days. Taken together, the TIL used in Study II might 
represent an ideal TIL product. 
 
4.4 Oncolytic adenovirus enhances TIL therapy of established pancreatic cancer (II) 
Following ex vivo culture and expansion of HapT1 TIL, we used the TIL together with the 
oncolytic adenovirus Ad5-D24 to study the therapeutic potential of these agents combined. First, 
cell killing was examined in vitro by infecting HapT1 cells with Ad5-D24 for 3 days before adding 
HapT1 TIL. 24 hours after this the viability of HapT1 target cells was determined. With this 
method we observed significantly improved cell killing with the combination of Ad5-D24 and 
TIL over the single agents (Figure 5, Study II). Encouraged by these results we proceeded to in 
vivo studies where HapT1 tumors implanted in Syrian hamsters were treated with the combination 
approach. Indeed, the combination treatment was superior to TIL or virus alone in controlling 
HapT1 tumor growth (Figure 6, Study II). Excitingly, analysis of endpoint spleens collected on 
Day 24 revealed an enhanced ex vivo tumor cell killing capacity in the group that received TIL 
plus Ad5-D24 treatment (Figure 7c, Study II). Also, a moderate increase in tumor-infiltrating 
CD8+ T-cells was observed in the combination-treated tumors (Figure 7b, Study II). 
The addition of checkpoint blockade antibodies to TIL therapy could prove an effective approach. 
This has been studied preclinically in mice where PD-L1 blockade and TIL transfer showed 
promising results (Kodumudi et al. 2016). However, the approach was not curative indicating that 
complementary treatment modalities are needed. Oncolytic adenoviruses might provide the 
solution, especially if armed with immunostimulatory cytokines. Another exciting approach to 
enhance the efficacy of adoptive TIL transfer is to transfect TIL with mRNA encoding chemokine 
receptors, such as CXCR3, for improved tumor migration (Idorn et al. 2016). Again, oncolytic 
viruses could aid in tumor-trafficking of transfected TIL by modulating chemokine expression 
indirectly (Study III) or directly if armed with chemokine-encoding transgenes (Nishio et al. 
2014). To conclude, the antitumor efficacy of TIL therapy can be enhanced with oncolytic 
adenovirus in a novel immunocompetent animal model supporting the clinical translation of this 
combination approach. 
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4.5 Armed adenovirus vectors produce high levels of tumor-restricted biologically active 
cytokines (III)  
Adoptive T-cell therapies have shown promising results in many indications, but the treament 
often comes with toxic side effects and not all patients benefit. Especially difficult to treat are 
solid tumors that feature a hostile immunosuppressive microenvironment for the adoptively 
transferred cells. In order to enable the full potential of T-cell therapy we set out to develop 
adenoviral vectors carrying immunostimulatory cytokines that could, when injected 
intratumorally, support the transferred T-cells locally at the tumor for enhanced efficacy. 
The constructed human serotype 5 –based non-replicating adenoviruses featured a promoter from 
human cytomegalovirus to drive constitutive expression of murine cytokines (Figure 1a, Study 
III). All cytokines (mIL-2, mTNFa, mIFNg and mIFNb) were produced in high concentrations in 
vitro and they were confirmed to be biologically active in appropriate bioassays (Figure 1b and 
Suppl. Figure S1, Study III). As an important feasibility and safety aspect we studied the 
expression of adenovirally delivered murine cytokines in vivo in mouse B16.OVA melanoma 
tumors. Adenoviruses injected into tumors produced high local levels of cytokines, yet systemic 
levels were negligible (Figure 1c-f, Study III).  
Tumor-restricted production of such potent cytokines as IL-2 and TNFa is of critical importance. 
Even though the viruses used in Study III are not specific for tumor cells per se, we did not observe 
systemic exposure, which has been shown to cause significant side effects including hypotension 
and hepatotoxicity (for TNFa)(Roberts et al. 2011), and vascular leakage syndrome (for IL-2)(Den 
Otter et al. 2008). Thus, local delivery of these cytokines with adenoviral vectors represents a 
safer approach. 
 
4.6 Cytokine-coding adenoviruses enhance adoptive T-cell therapy of murine melanoma by 
reshaping the tumor microenvironment and inducing T-cell trafficking (III) 
To assess the antitumor effects of cytokine-armed adenoviruses combined with T-cell transfer, we 
utilized the immunosuppressive B16.OVA melanoma model. Established B16.OVA tumors were 
treated with intratumoral injections of Ad5-CMV-mIL2, Ad5-CMV-mTNFa, Ad5-CMV-mIFNg, 
Ad5-CMV-mIFNb with or without intraperitoneal administration of T-cell receptor transgenic 
CD8+ enriched OT-I T-cells. The T-cell transfer alone was not effective in controlling tumor 
growth, but when combined with weekly injections of Ad5-CMV-mIL2 or Ad5-CMV-mTNFa, 
efficacy was significantly improved (Figure 2a-b, Study III). The aforementioned viruses coding 
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for mIL-2 and mTNFa showed the best antitumor effects as they were able, when coupled with 
OT-I T-cell transfer, to induce a stable non-progressing disease status in this aggressive melanoma 
model. In comparison, Ad5-CMV-mIFNg combined with OT-I cells did not achieve the same 
effect (Figure 2c, Study III). Also, treatment with Ad5-CMV-mIFNb did not bring any additional 
benefit to T-cell transfer as the virus itself was an effective therapeutic (Figure 2d, Study III). 
Based on experiments performed with viruses coding individual murine cytokines we then went 
out to combine the two best candidates to further improve antitumor efficacy together with T-cell 
transfer. These two cytokines were mIL-2 and mTNFa. Thus, in the same B16.OVA melanoma 
model we combined Ad5-CMV-mIL2 and Ad5-CMV-mTNFa in a 1 to 1 ratio with concomitant 
OT-I T-cell transfer and observed that this double combination of Ad5-CMV-mTNFa/Ad5-CMV-
mIL2 was superior to the mTNFa-armed virus combined with OT-I and the mIL-2-armed virus 
combined with OT-I (Figure 3, Study III). 
In mechanistic studies we studied the different cell types present in treated B16.OVA tumors. 
Lymphocyte subsets were first examined for CD4+ and CD8+ cells and we observed an increased 
number of CD4+ T-cells in tumors treated with mIL-2-coding virus plus OT-I (Figure 4a, Study 
III). CD8+ T-cell levels were higher in the mIL-2 and triple combination-treated groups (Figure 
4b, Study III). Interestingly, treatment with cytokine-armed viruses resulted in increased numbers 
of activated T-cells (i.e. CD3+ cells positive for CD69) infiltrating the tumors (Figure 4c, Study 
III). On the other hand, regulatory T-cell (Treg) infiltration was increased in triple combination-
treated tumors (Figure 4d, Study III). For B-cells and NK cells a similar pattern was observed; 
mIL-2-treated tumors contained the highest levels of these lymphocytes (Figure 4e-f, Study III). 
Low levels of immunosuppressive M2 macrophages were observed in tumors treated with 
combinations of cytokine-armed viruses and T-cells when compared with mTNFa and mIL-2 –
coding viruses (Suppl. Figure S2a, Study III). Moreover, the number of mature dendritic cells was 
increased in Ad5-CMV-mIL2 plus OT-I treated tumors (Suppl. Figure S2b, Study III). 
Immune checkpoint molecules PD1 and PD-L1 were also studied and we observed significant 
upregulation of PD-L1 expression in OT-I-treated tumors, which was further enhanced with the 
addition of adenoviruses (Figure 5a, Study III). The target of PD-L1 on T-cells, PD1, was shown 
to be downregulated on T-cells in mIL-2-treated tumors (Figure 5b, Study III). Lastly, the 
expression of chemokines was assessed in B16.OVA tumors following treatment with viruses and 
OT-I. When individual chemokine results were pooled (i.e. RANTES, MCP1, MIP-1a, MIP-1b, 
MIG and I-TAC) the combination treatment with Ad5-CMV-mTNFa plus OT-I showed 
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significant upregulation of these molecules when compared with OT-I alone (Figure 5c, Study 
III). 
The promising efficacy and immunophenotyping results motivated us to study further the fate of 
the transferred OT-I cells in vivo in the context of intratumoral adenovirus injections. To this end, 
we labelled OT-I cells with a radioactive isotope of indium (111Indium) and followed their tissue 
distribution in B16.OVA tumor-bearing mice with SPECT/CT imaging. 96 hours after treating 
mice with radiolabelled T-cells and cytokine-armed viruses we observed a significant 
accumulation of transferred T-cells in tumors treated with both viruses (Figure 6, Study III). 
In earlier studies performed in our group, we saw improved antitumor efficacy when adenovirus 
was combined with adoptive T-cell transfer in the B16 melanoma model (Tähtinen et al. 2015a). 
The adenovirus used in these studies was an unarmed one, and the efficacy was attributed to 
enhanced tumor immunogenicity, breaking of tumor-induced peripheral tolerance, and epitope 
spreading. Later, we studied adoptive OT-I transfer together with intratumorally injected 
recombinant cytokines (Tähtinen et al. 2015b). IFN-a2, IFNg, TNFa, and IL-2 significantly 
enhanced antitumor efficacy of OT-I therapy. The results indicated that these cytokines increased 
intratumoral cytokine secretion and recruited NK cells and mature DCs. Also, IFN-a2 and IL-2 
increased the numbers of activated CD8+ T-cells in tumors, while T-cell anergy markers CTLA-
4 and PD1 were downregulated on CD8+ TIL. In Study III, similar results were obtained with the 
newly constructed adenovirus vectors encoding murine TNFa and IL-2. 
As mentioned before, immunosuppressiveness of the tumor microenvironment poses a significant 
hurdle to adoptively transferred cells (Baitsch et al. 2011, Kalos & June 2013). Therefore, the 
local changes seen in a) PD1 expression, b) M2 macrophages, c) CD69+ T-cells, d) dendritic cells 
and e) chemokine expression hold much promise for future studies and possible human 
translation. The aforementioned alterations brought on by adenovirus injections coupled with the 
remarkable trafficking effect on T-cells could provide a solution for the well-known obstacle in 
the CAR T-cell therapy field: efficacy against solid tumors has been unimpressive despite 
breakthroughs in hematological malignancies (Beatty & O'Hara 2016). With regard to 
chemokines, preclinical and clinical studies have demonstrated the critical importance of 
chemokine/chemokine receptor expression in melanoma lesions for effective CD8+ T-cell 
responses (Harlin et al. 2009, Mikucki et al. 2015). 
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4.7 Oncolytic adenoviruses coding for human TNFa and IL-2 kill human and hamster 
cancer cells in vitro and synergize with hamster TIL (IV) 
The most promising immunostimulatory cytokines in the context of adoptive T-cell therapy were 
successfully identified in Study III. Thus, in Study IV, replication-competent oncolytic 
adenoviruses coding for human TNFa and IL-2 were constructed and used in combination with 
TIL transfer in immunocompetent Syrian hamsters.  As described earlier the Syrian hamster 
represents a significantly more relevant animal model for studying adenovirus-based gene therapy 
due to its ability to support replication of human adenovirus as opposed to mice. 
The new adenoviruses carry a backbone of Ad5/3-E2F-d24. The 24-base pair deletion in E1A and 
the E2F promoter renders virus replication specific to tumor cells (Figure 1a, Study IV). Cytokine 
transgenes were placed into the E3 region to yield viruses coding for human TNFa (Ad5/3-E2F-
d24-hTNFa), human IL-2 (Ad5/3-E2F-d24-hIL2), and both (Ad5/3-E2F-d24-hTNFa-IRES-
hIL2). A panel of human and hamster cancer cell lines were first used to assess the cell killing 
ability of the constructed adenoviruses. All viruses were able to kill cancer cells with similar 
efficacy as the virus without transgenes (Figure 1b, Suppl. Figure S1, Study IV). In addition, 
HapT1-derived TIL were studied together with the adenoviruses to assess combination effects in 
vitro and we observed synergistic cell killing with combinations of TIL and adenovirus (Figure 
1c, Study IV). Expression and bioactivity of adenovirus-encoded human cytokines were 
confirmed both in vitro and in vivo (Figure 2a-b, Suppl. Figure S2, Study IV). From a safety 
perspective it is noteworthy that cytokine levels were undetectable in sera of intratumorally 
injected hamsters while tumor levels were high, indicating that cytokine production is strictly 
limited to tumors (Figure 2c, Study IV). 
Synergistic tumor cell killing with TIL and adenovirus in vitro was also observed in Study II. The 
mechanism of synergy was not studied further in either of the two studies, although it is expected 
to differ from the more complex in vivo situation. Previous research with IL-12 –encoding 
adenovirus and cytokine-induced killer (CIK) cells showed improved cell killing in vitro as well, 
but mechanistic studies were not pursued (Yang et al. 2012). More recently, the combination of 
Ad5-D24 and CAR T-cells was investigated in several human tumor cell lines, and the superior 
cell killing that was observed was associated with accelerated caspase pathways (Nishio et al. 
2014). The mechanism of synergy between adenoviruses and hamster TIL in Studies II and IV 
might bear similar features, but this requires further examination.  
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Clinical adoptive T-cell transfer protocols include high-dose IL-2 administered intravenously 
following the transfer (Rosenberg 2014). This postconditioning regimen is considered essential 
for the T-cell graft, but it is accompanied by severe toxicities on the systemic level. For this reason, 
the possibility of circumventing the need for systemic IL-2 by local delivery would represent a 
notable safety improvement. In Study III we utilized non-replicating adenoviral vectors to deliver 
IL-2 (and TNFa), and we observed that cytokine production was limited to tumors. 
Correspondingly, the oncolytic viruses constructed and used in Study IV showed tumor-restricted 
IL-2 expression with no systemic exposure. This observation was not surprising since cytokine 
production from an oncolytic adenovirus platform has been shown to be contained to tumors 
(Koski et al. 2010). Thus, in future studies, a head-to-head comparison between adenovirally 
delivered IL-2 and systemically administered IL-2 should be performed in the context of adoptive 
T-cell transfer. For this approach to be considered a competitive option to traditional systemic 
administration, antitumor efficacy needs to be non-inferior, if not superior. 
In addition to postconditioning IL-2, non-myeloablative chemotherapy consisting of 
cyclophosphamide and fludarabine is typically included as “preconditioning” for patients 
undergoing adoptive T-cell transfer (Hershkovitz et al. 2010). As with IL-2, preconditioning is 
associated with toxicities. To date, it has not been studied whether local oncolytic adenovirus 
injections could also replace the need for systemic chemotherapy prior to T-cell transfer. 
Preclinically this aspect can be assessed in mice using cytokine-coding non-replicating viruses 
described in Study III or in Syrian hamsters using oncolytic viruses described in Study IV. 
 
4.8 Armed oncolytic adenoviruses exhibit potent antitumor activity against ovarian cancer 
xenografts and Syrian hamster pancreatic cancer (IV) 
Antitumor efficacy of the new armed adenoviruses was studied in two different animal models. 
First, a xenograft model for orthotopic ovarian cancer was employed to study the effects against 
tumors of human origin. SCID mice bearing luciferase-expressing SKOV3-Luc tumors were 
treated with intraperitoneal injections of Ad5/3-E2F-d24, Ad5/3-E2F-d24-hTNFa, Ad5/3-E2F-
d24-hIL2 or Ad5/3-E2F-d24-hTNFa-IRES-hIL2 once per week. All viruses displayed potent 
efficacy despite the inclusion of transgenes (Figure 3, Study IV). Differences between viruses 
were not significant, since immunostimulatory cytokines are not expected to have downstream 
adaptive response effects in an immunocompromised animal lacking a full immune system. 
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Since Syrian hamsters support human adenovirus replication, the logical next step was to assess 
antitumor efficacy in hamsters with or without TIL transfer. The unarmed virus had very little 
efficacy, as did TIL transfer alone, but when combined a highly effective response was observed 
(Figure 4a, Study IV). The armed viruses showed very potent antitumor efficacy even as single 
agents (Figure 4b-d, Study IV). However, the percentage of cured animals was higher in groups 
receiving TIL and virus compared with virus-only groups (Figure 4e, Study IV). This observation 
was confirmed in histopathological post-mortem analysis, which revealed that 100% of hamsters 
treated with Ad5/3-E2F-d24-hTNFa-IRES-hIL2 and TIL were cured of tumors. Similar results in 
antitumor efficacy were obtained when a reduced virus dose was used (Figure 4f, Study IV). 
The ovarian cancer model (SKOV3) used in Study IV has been studied extensively in the context 
of adenovirotherapy (Bauerschmitz et al. 2002, Kanerva et al. 2003, Kanerva et al. 2005, Raki et 
al. 2005, Raki et al. 2008). It has proven useful for orthotopic gene therapy studies despite its 
tendency to gain resistance to adenovirus, that was shown to arise through induction of interferon 
pathways (Liikanen et al. 2011). A rational combination therapy to be studied preclinically in the 
SKOV3 model would involve CAR T-cells (targeted against over-expressed epitopes on ovarian 
cancer) and Ad5/3-E2F-d24-hTNFa-IRES-hIL2. Recently, L1-CAM –specific CAR T-cells were 
used against SKOV3 implanted in NOD scid gamma (NSG) mice with promising results (Hong 
et al. 2016). However, the CAR T-cells did not eradicate all tumors leaving room for 
combinatorial approaches that would logically include oncolytic adenoviruses. 
 
4.9 Cytokine-armed oncolytic adenoviruses induce tumor-specific antitumor immunity and 
increased splenocyte proliferation (IV) 
Endpoint tumors and organs were collected from Syrian hamsters to gain understanding of the 
observed antitumor efficacy. Interestingly, CD8+ and CD4+ T-cells were more frequent in tumors 
treated with IL-2-coding adenovirus (Figure 5a-b, Study IV). In lymph nodes and spleens the 
changes in cell composition were less pronounced (Suppl. Figure S3, Study IV). Additionally, 
splenocyte proliferation ex vivo was significantly increased when the animals were treated with 
cytokine-coding viruses (Figure 5d, Study IV).  
Those hamsters that were previously cured of HapT1 tumors were subjected to rechallenge with 
the same tumor and another tumor (DDT1-MF2), after a two-week rest period. The animals treated 
and cured with cytokine-armed viruses were able to reject HapT1, whereas the one animal cured 
with the unarmed virus had a non-progressing disease status (Figure 6a, Study IV). Importantly, 
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the growth of DDT1-MF2 tumors in cured animals was comparable to growth in naïve animals 
(Figure 6b, Study IV). Together, these data indicate that treatment with cytokine-coding oncolytic 
adenoviruses induce tumor-specific antitumor immunity. 
For the assessment of safety, histopathological analysis of key organs was performed by a 
veterinary pathologist. Mild and minimal lymphocyte hyperplasia, slightly expanded white pulp, 
and mildly increased number of heterophils in the marginal zone or red pulp were observed in 
spleens of all treatment groups (data not shown). Treatment-related changes in tissue structures 
of heart, lung, liver, and kidney were absent indicating that treatment with cytokine-armed 
adenoviruses was safe. 
Previously, an oncolytic adenovirus coding for GMCSF (Ad5-D24-GMCSF) was studied in 
Syrian hamsters with HapT1 tumors (Cerullo et al. 2010a). As in Study IV, the animals treated 
with Ad5-D24-GMCSF were cured and later rechallenged with the same tumor and with a 
different tumor (HaK). The results were very similar in this rechallenge experiment as in Study 
IV, i.e. the cured animals were able to reject the same tumor but not the new one. Comparable 
results have been reported with oncolytic vaccinia virus coding for GMCSF (Parviainen et al. 
2015).  
Future studies should focus on utilizing Syrian hamsters to their full extent. Sequencing and 
annotation of the hamster transcriptome enables construction of CAR T-cells targeting epitopes 
present on several implantable tumors of various histologies, and subsequent combination studies 
with oncolytic adenoviruses (Tchitchek et al. 2014). Moreover, the development of assays to 
monitor immune responses in Syrian hamsters significantly increases the translational value of 
this animal model within the cancer immunotherapy field (Zivcec et al. 2011). 
One potential application (in addition to T-cell therapy enhancement) for the TNFa/IL-2 –coding 
adenovirus constructed in Study IV relates to a hot topic in oncology that is immune checkpoint 
blockade. The predictive biomarkers for benefiting from checkpoint blockade treatment have been 
identified: tumor CD8+ infiltration and PD-L1 upregulation (Spranger 2016). As shown in Study 
III, both of these markers are influenced by cytokine-coding adenoviruses even in the absence of 
true oncolysis. In Studies II and IV, only one of these key phenomena (CD8+ infiltration) could 
be studied due to lack of tools for detecting hamster PD-L1. Nevertheless, armed oncolytic 
adenoviruses (such as the one described in Study IV) have the potential of making checkpoint 
blockade therapy work by converting “cold” tumors to “hot” tumors (Zamarin et al. 2014). Other 
oncolytic viruses have been recently studied with checkpoint-blocking antibodies: measles virus 
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with CTLA-4 and PD-L1 blockade (Engeland et al. 2014), Semliki Forest Virus with PD1 
blockade (Quetglas et al. 2015), and reovirus with PD1 blockade (Rajani et al. 2016). To date, 
clinical experience with oncolytic virus and checkpoint blockade combination is limited, yet 
encouraging reports are emerging: T-VEC (HSV-1 –based oncolytic virus) combined with 
pembrolizumab (anti-PD1 mAb) in unresectable stage IIIB-IV melanoma patients resulted in a 
50% response rate (Long et al., Abstract 9568, 2016 ASCO Annual Meeting). Combinatorial 
clinical studies with many other viruses are underway and the results are eagerly awaited (Lawler 
et al. 2016). 
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5. SUMMARY AND CONCLUSIONS  
 
The editors of Science selected cancer immunotherapy as the Breakthrough of the Year for 2013 
(Couzin-Frankel 2013). Despite the evident progress, much work remains to be done to improve 
cure rates further, and to identify the right treatment for each individual patient. It has become 
clear that rational combinations of treatment modalities are the key to success, as exemplified by 
clinical trials with: two checkpoint-inhibiting antibodies versus only one (Larkin et al. 2015, 
Postow et al. 2015), checkpoint inhibitor combined with chemotherapy (Rizvi et al. 2016), and 
oncolytic virus combined with checkpoint inhibition (Long et al., Abstract 9568, 2016 ASCO 
Annual Meeting). However, the safety of effective novel treatments (and their combinations) 
needs to be carefully evaluated in order to avoid unexpected toxicities such as the ones reported 
with TCRs and CARs (Linette et al. 2013, Kochenderfer et al. 2012), and checkpoint inhibitors 
(Spain et al. 2016). Importantly, the safety profile of oncolytic adenoviruses has been considered 
excellent (Pesonen et al. 2011), and in some cases dose-limiting toxicities (DLT) or maximum 
tolerated doses (MTD) have not even been reached (Ranki et al. 2016). 
In this thesis we show that oncolytic adenovirus encoding a potent immunostimulatory cytokine, 
GM-CSF, synergizes with standard first-line chemotherapy against soft-tissue sarcomas of human 
and Syrian hamster origin (Study I). We provide clues on the mechanism-of-action and suggest 
that this combination treatment is not only effective but also safe for clinical translation. In the 
second study, TIL were successfully cultured from syngeneic Syrian hamster tumors and 
subsequently used together with oncolytic adenovirus injections to treat established pancreatic 
cancer. With this approach, improved antitumor efficacy was achieved as compared with the 
single agents, and the treatment was safe. When oncolytic adenoviruses armed with the human 
cytokines IL-2 and TNFa were combined with TIL transfer in Study IV, complete tumor 
eradication and tumor-specific immunity was induced. In Study III, adenovirus vectors coding for 
murine IL-2 and TNFa enhanced T-cell therapy of immunosuppressive mouse melanoma similar 
to many human melanomas, with indications that T-cell trafficking to tumors was improved by 
the cytokines and that the combination treatment ameliorated local tumor-induced 
immunosuppression. In conclusion, the preclinical results presented in this thesis strongly support 
the translation of adenovirus-based cancer immunotherapy combinations into patient care. 
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